WO2018226565A1 - Dispositif d'administration de médicament entraîné par couple - Google Patents

Dispositif d'administration de médicament entraîné par couple Download PDF

Info

Publication number
WO2018226565A1
WO2018226565A1 PCT/US2018/035816 US2018035816W WO2018226565A1 WO 2018226565 A1 WO2018226565 A1 WO 2018226565A1 US 2018035816 W US2018035816 W US 2018035816W WO 2018226565 A1 WO2018226565 A1 WO 2018226565A1
Authority
WO
WIPO (PCT)
Prior art keywords
assembly
plunger rod
plunger
rod guide
injector
Prior art date
Application number
PCT/US2018/035816
Other languages
English (en)
Inventor
Adam B. Mccullough
Ronald Forster
Joseph Michael Iglesias
Matias Melander
Rasmus ØHLENSCHLAEGER
Christian Plambech
Lars Stenholt
Bjarke Lykke LUDVIG SVENDSEN
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to EP18733474.3A priority Critical patent/EP3634546A1/fr
Priority to US16/609,466 priority patent/US11904143B2/en
Priority to JP2019561838A priority patent/JP7200134B2/ja
Priority to CA3066399A priority patent/CA3066399A1/fr
Priority to CN201880036742.6A priority patent/CN110709121B/zh
Priority to MX2019014615A priority patent/MX2019014615A/es
Priority to AU2018282077A priority patent/AU2018282077B2/en
Publication of WO2018226565A1 publication Critical patent/WO2018226565A1/fr
Priority to JP2022202914A priority patent/JP2023030073A/ja
Priority to AU2024201097A priority patent/AU2024201097A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/3145—Filters incorporated in syringes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3143—Damping means for syringe components executing relative movements, e.g. retarders or attenuators slowing down or timing syringe mechanisms

Definitions

  • the present disclosure generally relates to injectors and, more particularly, to a torque driven injector optionally having a damper mechanism and a filtering device.
  • Autoinjectors and on-body injectors offer several benefits in delivery of medicaments and/or therapeutics.
  • One of the benefits can include simplicity of use, as compared with traditional methods of delivery using, for example, conventional syringes.
  • a patient may feel this excessive energy as a "slap” or similar physical “bump", as the spring driven plunger impacts the stopper of the primary container storing the drug. Further, the user may also experience a jerk, recoil, and/or a reaction force when rotational movement begins due to the abrupt change in acceleration. Such mechanical bumps can be distracting and/or disturbing to users of the injectors and can therefore impact proper dose administration. Further, the "slap” and “bump” generated by the excessive energy can potentially cause catastrophic effects, such as breakage of the primary container and drug product damage cause by shear load. Furthermore, high force springs can produce undesirably high shear rates on the drug product.
  • an injector in accordance with a first aspect, includes a housing having a syringe assembly and an actuating mechanism at least partially disposed within the housing.
  • the syringe assembly can include a syringe barrel that stores a medicament to be injected into a user, a needle assembly, and an optional filter member disposed adjacent to the needle assembly.
  • the actuating mechanism is operatively coupled to the syringe assembly and includes a torque spring that exerts a torque that urges the medicament through the filter member to be injected into the user.
  • the actuating mechanism further includes a damper mechanism that exerts an opposing force or torque to dampen the torque exerted by the torque spring.
  • the syringe barrel has a first end, a second end, and a longitudinal axis.
  • the needle assembly is coupled to the second end of the syringe barrel, and includes a needle hub and a needle attached to the needle hub.
  • the filter member restricts particles dispersed within the medicament from entering the needle assembly.
  • the actuating mechanism further includes a frame member, a plunger assembly that includes a threaded plunger rod and a plunger face, and a plunger rod guide.
  • the frame member is coupled to the housing and has a threaded opening formed between a first surface and a second surface thereof.
  • the threaded plunger rod threadably couples to the threaded opening of the frame member.
  • the plunger face is disposed near the first end of the syringe barrel.
  • the plunger assembly is moveable along the longitudinal axis of the syringe barrel.
  • the plunger rod guide is coupled to the plunger assembly to guide rotational movement of the plunger assembly, and to transfer a torque. As the plunger rod guide rotates due to a torque exerted by the torque spring, the plunger assembly advances towards the syringe barrel to urge the medicament through the filter and the needle assembly.
  • the filter member is at least partially disposed within a portion of the needle hub and includes a plurality of openings to allow the medicament to pass through while restricting particles dispersed within the medicament from passing through. Any number of these openings may have a diameter of between approximately ⁇ and approximately 50 ⁇ .
  • the openings may be of any shape or configuration such as conical, cylindrical, etc.
  • the torque spring may be tightly wound, having between approximately 1 and approximately 30 turns.
  • a tightly wound torque spring By using a tightly wound torque spring, a consistent amount of torque is generated throughout the actuation process.
  • the threaded plunger rod and/or the threaded opening of the frame member may have a thread pitch between approximately 2mm and approximately 6mm, which, when combined with the tightly wound torque spring (and the damper), impart high forces on the medicament at a low velocity, thus reducing overall impact speed between the plunger face and the syringe barrel.
  • the damper mechanism may include a viscous material disposed between a portion of the plunger rod guide and the housing.
  • the damper mechanism may alternatively be disposed between a different rotating element and the housing, a linear moving element and the housing, or two any other elements that move relative to each other.
  • the damper mechanism includes a deformation region adapted to at least partially deform as the plunger assembly advances towards the syringe barrel.
  • the damper mechanism includes a rotating or linear damping device disposed between the plunger rod guide and the plunger assembly.
  • a syringe assembly for an injector that additionally includes a housing having an actuating mechanism at least partially disposed within the housing and being coupled to the syringe assembly.
  • the syringe assembly includes a syringe barrel, a needle assembly, and a filter member.
  • the syringe barrel has a first end, a second end, and a longitudinal axis, and stores a medicament to be injected into a user.
  • the needle assembly is coupled to the second end of the syringe barrel, and includes a needle hub and a needle attached thereto.
  • the filter member is disposed adjacent to the needle hub. The filter member restricts particles dispersed within the medicament from entering the needle assembly.
  • an actuating mechanism for an injector that additionally includes a housing having a syringe assembly at least partially disposed within the housing and being coupled to the actuating mechanism.
  • the actuating mechanism includes a frame member, a plunger assembly, a plunger rod guide, a torque spring, and a damper mechanism.
  • the frame member is coupled to the housing, and has a threaded opening formed between a first surface and a second surface.
  • the plunger assembly includes a threaded plunger rod and a plunger face. The threaded rod threadably couples to the threaded opening of the frame member.
  • the plunger face is disposed near the syringe assembly.
  • the plunger rod guide is coupled to the plunger assembly to guide rotational movement of the plunger assembly and to transfer a torque thereto.
  • the torque spring is coupled to the plunger rod guide to exert a torque on the plunger rod guide that causes the plunger rod guide to rotate.
  • the damper mechanism is formed by at least a portion of the plunger rod guide or a part coupled to the plunger rod guide. Upon the torque spring exerting a torque on the plunger rod guide, the damper mechanism exerts an opposing force on the plunger rod guide to reduce an impact force and/or speed between the plunger assembly and the syringe assembly.
  • FIG. 1 illustrates an example torque driven injector having a damper mechanism and a filter member in accordance with various embodiments
  • FIG. 2a illustrates a perspective view of an example filter member in accordance with various embodiments
  • FIGS. 2b and 2c illustrate cross-sectional views of example filter member arrangements in accordance with various embodiments
  • Fig. 2d illustrates a cross-sectional view of an alternate filter member arrangement where the filter member is an elevated platform in accordance with various embodiments
  • FIG. 2e-2h illustrate views of an alternate filter member arrangement in accordance with various embodiments
  • Figs. 3a and 3b illustrate cross-sectional views of example filter member placements within a syringe assembly of the torque driven injector of Fig. 1 in accordance with various embodiments;
  • Figs. 4a-4c illustrate cross-sectional views of a portion of example actuating mechanisms of the torque driven injector of Fig. 1 in accordance with various embodiments;
  • Figs. 5a-5g illustrate example damper mechanisms of the torque driven injector of Fig. 1 in accordance with various embodiments
  • Fig. 6 illustrates an alternate torque driven injector having a spring guide mechanism
  • Fig. 7 illustrates a cross sectional view of the example torque driven injector of claim 6
  • FIGs. 8a and 8b illustrate a torque driven injector having an alternative spring guide mechanism in accordance with various embodiments
  • Fig. 9 illustrates a torque driven injector having an alternative spring guide mechanism in accordance with various embodiments.
  • a torque driven injector includes a housing, a syringe assembly containing a medicament to be injected into a user, and a rotatable actuating assembly using a torque spring to cause the medicament to be injected into the user.
  • an optional filter mechanism may restrict any unwanted foreign particles in the medicament from being injected into the user. So configured, the filter mechanism can reliably mitigate the risk of injecting unwanted foreign particles into the user.
  • a damper mechanism reduces or eliminates the "slap” or “bump” that occurs when the plunger face first contacts the medicament and/or medicament storage device.
  • the damper mechanism may also reduce the "jerk” or recoil when the mechanism is released. Accordingly, a user will not feel this sudden movement during the drug delivery process, and can comfortably and safely administer the medicament.
  • the torque spring which uses a high number of turns, discussed in further detail below, may maintain near-constant start and end torque as compared to traditional springs and those with fewer turns. As a result, smaller autoinjectors may be used, which can increase overall user comfort.
  • an example autoinjector 100 includes a housing 102 having a syringe assembly 110 and an actuating mechanism 150. At least a portion of the syringe assembly 110 and the actuating mechanism 150 are disposed within the housing 102.
  • the syringe assembly 110 includes a syringe barrel 112, a needle assembly 114, and an optional filter member 120 disposed adjacent to the needle assembly 114.
  • the actuating mechanism 150 includes a frame member 152, a plunger assembly 160, a plunger rod guide 170, a torque spring (e.g., a power spring) 180, and an optional damper mechanism 190.
  • the syringe barrel 112 stores a medicament to be injected into a user, and has a first end 112a, a second end 112b, and a longitudinal axis "L".
  • the syringe barrel 112 further includes a base 112c and a sidewall 112d that define a cavity to store the medicament.
  • the syringe barrel 112 may include at least one opening 112e disposed through the base 112c to allow the medicament to pass into the needle assembly 114.
  • the first end 112a of the syringe barrel 112 may be open to accommodate the plunger assembly 160, which will be described in further detail below.
  • the syringe barrel 112 may be any desired shape and/or size to accommodate various quantities of medicament.
  • the syringe barrel 112 can be constructed from a cyclic-olefin polymer ("COP"). Other examples of materials are possible.
  • the needle assembly 114 is coupled to the second end 112b of the syringe barrel 112 via any type of coupling mechanism and/or structure, and includes a needle hub 116 and a needle 118 attached thereto.
  • the needle hub 116 defines a cavity that allows medicament to enter into the needle 118 via any number of openings 118a.
  • the needle hub 116 is positioned below the opening 112e formed in the base 112c of the syringe barrel 112. So configured, the needle hub 116 receives the medicament as it exits the syringe barrel 112, which then enters into the needle 118 to be administered to the user.
  • the injector 100 may include any number of additional components such as return springs, needle shields and/or guards, and the like to assist in administering the medicament to the user. For the sake of brevity, these additional components will not be discussed in substantial detail.
  • the filter member 120 is disposed adjacent to the syringe barrel 112 and the needle assembly 114.
  • the filter member 120 may be disposed directly within the opening 112e formed in the base 112c of the syringe barrel 112.
  • the filter member 120 may be disposed within a portion of the cavity defined by the needle hub 116, distally beyond the base 112c of the barrel 112.
  • the filter member 120 may be positioned between the base 112c of the syringe barrel 112 and the needle hub 116.
  • the filter member 120 may be positioned within the syringe barrel 112, and occupy substantially the entire cross-sectional area of the syringe barrel 112.
  • the filter member 120 may be generally cylindrically and/or wafer shaped.
  • the filter member 120 may be constructed from a polymer such as polyvinylidene fluoride (PVDF), though other examples of materials are possible.
  • PVDF polyvinylidene fluoride
  • the filter member 120 may include an upper surface 120a, a lower surface 120b, and a sidewall 120c connecting the upper surface 120a and the lower surface 120b.
  • the filter member 120 also includes a number of pores or openings 122 to allow the medicament to pass through (e.g., from the opening 112e of the syringe barrel 112, through the upper surface 120a, and to the lower surface 120b) while restricting particles dispersed within the medicament from passing through.
  • each of the openings 122 may have a diameter, length, or other cross- sectional dimension (denoted by reference “D” in Fig. 2b) of between approximately ⁇ and approximately 50 ⁇ , and preferably, between approximately 15 ⁇ and approximately 30 ⁇ .
  • D diameter, length, or other cross- sectional dimension
  • the openings 122 may be dimensioned as desired in order to properly filter particles of desired sizes from the medicament.
  • the openings 122 are generally parallel in shape. Put another way, the diameter of the openings 122 disposed on both the upper surface 120a and the lower surface 120b are approximately equal. As such, the openings 122 are generally cylindrical in shape. It is understood, however, that the openings 122 may be of any shape such as cuboid, prismatic, etc. In this example, any particles that are larger than the dimension D will be restricted from passing through the openings 122, and will instead rest against the upper surface 120a of the filter member 120.
  • the diameter, length, or other cross- sectional dimension (denoted by reference “D 2 ”) of the opening disposed through the upper surface 120a of the filter member 120 is larger than the opening (denoted by reference “Di") disposed through the lower surface 120b.
  • the openings 122 may be, for example, partially conically shaped. In these examples, any particles which are larger than the dimension D 2 will not be able to pass therethrough, and instead will remain disposed within cavity formed by the opening 122. It is understood that any arrangement of the openings 122 illustrated in Figs. 2b and 2c may be used separately or in combination.
  • the openings disposed through the upper surface 120a of the filter member 120 is smaller than the opening disposed through the lower surface 120b. So configured, the medicament would first flow through the smaller diameter side and out through the larger diameter side, thereby exhibiting divergent flow characteristics. Accordingly, particles would not be caught or in trapped in the conical tube, thereby reducing pressure loss, which in turn may result in less power needed to expel the medicament.
  • the filter member 120 may also include a coupling mechanism 124 disposed on the sidewall 120c to secure the filter member 120 at the desired location within the injector 100.
  • the coupling mechanism 124 may be formed integrally with the filter member 120, or it may be a distinct component.
  • the coupling mechanism 124 is an annular protrusion or ring that inserts into a corresponding notch or groove (not shown) formed in the desired component (e.g., the opening 112e formed in the base 112c of the syringe barrel 112, the needle hub 116, etc.).
  • the desired component e.g., the opening 112e formed in the base 112c of the syringe barrel 112, the needle hub 116, etc.
  • Other coupling mechanisms 124 are possible.
  • the coupling mechanism 124 may restrict axial movement along axis L in any direction.
  • the coupling mechanism 124 may be a
  • the coupling mechanism 124 may only restrict axial movement along axis L in the downward direction, that is, when the medicament is being ejected from the injector 100. Because the syringes are pre-filled, it may not be necessary to have a multidirectional locking mechanism because such a component may increase overall costs.
  • any number (one or more) of the openings 122 may include rounded, beveled, and/or chamfered regions 122a where the upper surface 120a forms the opening 122. So configured, the filter member 120 will not cause the larger, undesirable particles to be broken into smaller sizes when passing through the filter member 120, which may potentially allow the particle to pass through the filter member 120 and into the user.
  • the filter member 120 may be disposed within a portion of the syringe barrel 112.
  • the filter member 120 includes an elevated or shelf portion 120d. so configured, the lower surface 120b of the filter 120 is disposed a distance (denoted by "h" in Fig. 2d) away from the second end 112b of the syringe barrel 112. This configuration may provide for smoother flow of the medicament when being administered to the user.
  • the filter assembly includes a retention ring 120e (Fig. 2f), a filter sheet 120f (Fig. 2g), and a support member 120g (Fig. 2h).
  • the retention ring 120e is adapted to retain the filter sheet 120f in place and to restrict upward lateral movement of the filter sheet 120f.
  • the filter sheet 120f may be porous and have a porosity to allow fluid to flow therethrough while restricting particles within the medicament.
  • the filter sheet 120f may rest on the support member 120g, which may have a central support structure 120h in the form of a web that separates its opening into four quadrants 120L By dividing the opening into quadrants and providing the support structure 120h, flexure of the filter sheet 120f is limited when it is under a high differential pressure, and thus will not have an impact on fluid flow. Further the support structure 120h minimizes any fluid flow-restricting surface areas. As illustrated in Fig. 2e, the support member 120g may have a raised portion 120j that acts as a relief and allows fluid flow between the individual quadrants.
  • the frame member 152 of the actuating mechanism 150 may be fixedly coupled to the housing 102 via any number of approaches.
  • the frame member 152 may be formed integrally with the housing 102.
  • the frame member 152 may include a first surface 152a, a second surface 152b, and a threaded opening 152c formed between the first surface 152a and the second surface 152b.
  • the plunger assembly 160 is moveable along the longitudinal axis L of the syringe barrel 112, and includes a plunger rod 162 having a threaded portion 162a which is threadably coupled to and is disposed within the threaded opening 152c of the frame member 152.
  • the threaded portion 162a of the plunger rod 162, and correspondingly, the threaded opening 152c of the frame member 152 may have a thread pitch suitable for any desired drug delivery rate or force/torque combination when driven by the torque spring 180. Relative rotation between the plunger rod 162 and the frame member 152 causes the plunger rod 162 to advance axially.
  • the plunger assembly 160 further includes a plunger face 164 that is disposed near the first end 112a of the syringe barrel 112.
  • the plunger rod guide 170 includes a rod portion 172 and a cup portion 174 coupled thereto.
  • the rod portion 172 of the plunger rod guide 170 is coupled to the plunger assembly 160 via any number of approaches including, for example, via a splined connection or slotted arrangement that allows for the plunger assembly 160 to be axially displaced relative to the plunger rod guide 170.
  • the plunger rod guide 170 guides rotational movement of the plunger assembly 160.
  • the cup portion 174 of the plunger rod guide 170 is adapted to at least partially surround and rotate about the frame member 152 and assists with maintaining alignment of the interconnected moving components.
  • the cup portion 174 needn't surround the frame member 152, rather, damping components may be axially aligned with each other.
  • the cup portion 174 may take any suitable shape or configuration. In these examples, relative motion between the damping components and the cup portion 174 may provide adequate damping forces.
  • An inner portion 180a of the torque spring 180 is coupled to the rod portion 172 of the plunger rod guide 170 via any known approach to exert a force on the plunger rod guide 170 causing the plunger rod guide 170 to rotate about axis L.
  • the torque spring 180 may have a high number of turns to provide an appropriate rotational travel required to expel the medicament from the syringe barrel 112, however, additional parameters of the spring design may influence its torque output such as material properties and any applied heat treatments. The pre-shaping of the torque spring 180 may also impact its performance.
  • a pre-stressed spring may be preferred, because the pre-stressing process generally increases torque output of the spring by initial coiling the spring in an opposite direction of the intended working condition, thereby causing permanent deformation in the steel band. This deformation maximizes the stresses in the material, thereby causing the torque to increase. Such an increase in torque is beneficial to minimize device size and weight.
  • the torque spring 180 may have between approximately 1 and approximately 30 turns in the wound or loaded configuration, and preferably, approximately 12 turns. In some examples, the total spring turns may be higher due to a margin in both ends of the working range of approximately 20%, which may result in the range being between
  • the torque spring 180 may have a number of initial, or preload turns to have a usable torque. After the preload turns, the torque spring 180 is further wound with working turns, or turns that are used in the device during injection. As a non-limiting example, the torque spring 180 may have approximately 2.5 preload turns and approximately 6 working turns. As such, the total number of turns during assembly is
  • the torque spring 180 may have an initial play before reaching a solid state, and thus may have a total of approximately 10 turns.
  • Devices having different drug volumes and viscosities may need a different average torque generated from the torque spring 180 if the same dosing is desired.
  • the average torque output may be controlled by adjusting the width of the band used for the torque spring 180 (e.g., the axial length of the torque spring 180 when disposed in the device), and maintaining the same number of working turns. Doing so may allow different springs to be used with the same configuration as the device and have similar injection times while the volume and/or viscosity of the drug may be modified.
  • the energy (E FLOW ) required to expel the drug through a needle is determined by any combination of the drug volume, viscosity, needle flow path dimensions, and the targeted dosing time.
  • the energy (E SPRING ) that the torque spring 180 delivers may be determined by any combination of the number of working turns (N) and the average spring torque during the working turns (T).
  • the threaded interface between the plunger rod 162 and the frame member 152 provides a translation between the input torque of the torque spring 180 and the output axial force.
  • a torque spring 180 With a high turn count, it will have a lower overall torque as well as a smaller change in start and end torque as compared to a linear spring having comparable gearing specifications or other torsion springs with few turns and a lower pitch.
  • the threads of the plunger rod 162 and the frame member 152 can have a lower pitch due to the increase in turn count, while still achieving the same linear motion of the plunger assembly 160. If the thread pitch is low, a smaller input torque is necessary to provide the same output force as a high pitch thread and high torque spring.
  • the high turn count (e.g., between approximately 1 and approximately 30 turns), low torque system described herein allows for reduced activation forces, as the activation force is directly related to the input torque that must be used to drive the plunger assembly 160.
  • internal structural forces required to resist the torque from the torque spring 180 during storage is reduced, thus allowing for smaller injector designs to be used and for less expensive raw materials to be used.
  • the increase in turns can lead to a more flexible dampening system (which will be described in further detail below) due to the increase in velocity between the components thereof.
  • the threaded interface between the plunger rod 162 and the frame member 152 allows the threaded plunger rod to be adjusted to accommodate for varying quantities of medicament stored in the syringe barrel. If necessary, the threaded plunger rod 162 may be initially installed at a lower position in injectors 100 having lesser drug product volumes disposed in the syringe barrel 112. Accordingly, the number of unique components is reduced, and variation management is simplified. The threaded plunger rod 162 may also be adjustably installed at various depths during the manufacturing and/or assembly process as needed.
  • Figs. 4a-5g the damper mechanism 190 opposes the torque exerted on the plunger rod guide 170 by the torque spring 180.
  • the damper mechanism 190 can have any number of configurations.
  • Figs. 4a and 5a illustrate a damper mechanism 190a in the form of a viscous fluid being disposed in an area between an inner surface 102a of the housing 102 and an outer surface 174a of the cup portion 174 of the plunger rod guide 170.
  • the viscous fluid 190a may be disposed at any location along the area between the housing 102 and the cup portion 174, and in some examples may be contained in an area or chamber 190b.
  • the chamber 190b may be sealed in some embodiments, and in other embodiments, the chamber 190b may be unsealed.
  • an unsealed chamber may be preferred because sealed viscous dampers inherently introduce frictional resistance, which may not be speed dependent or may actually reduce with higher speeds which is the opposite of the design intent. This means at low speed delivery when the medicament is providing the most resistance the seal may continue to contribute measurable frictional resistance. Unsealed dampers will likely have fewer components and more of the resistive force will behave according to the intent where higher speeds create higher damping force and lower speeds create lower damping force. As illustrated in Fig. 5a, the cup portion 174 may have protrusions 174a that contact the inner surface 102a of the housing 102.
  • protrusions 174a effectively restrict the viscous fluid within the chamber 190b to reduce or eliminate the possibility of the viscous fluid 190a leaking within the housing 102.
  • any number of viscous fluids having varying viscosities may be used to achieve a desired amount of dampening depending on the desired configuration of the injector 100 and the medicament contained within the syringe barrel 112.
  • a "motion control" damping viscous fluid 190a or grease may be provided that has a high viscosity at low shear, resulting in yield stress that allows the viscous fluid 190a to remain stationary during transport while providing sufficient damping during actuation.
  • a suitable damping viscous fluid 190a can include Nyemed 7325, manufactured by Nye Lubricants.
  • the viscous fluid 190a may be disposed at other locations, such as between the housing 102 and the rod portion 172 of the plunger rod guide 170. Further, the viscous fluid may be disposed in a gap between two components having relative motion during extrusion of the medicament such as in the threaded interface between the threaded plunger rod 162 and the frame member 152. In some examples, the length of the gap is at least approximately three times as large as the width of the gap.
  • the viscous fluid 190a may be disposed in a void or chamber 190c between an upper frame member 184 and a rotating member 186 disposed in or near a cap 102b of the housing 102.
  • the upper frame member 184 is fixed to the housing 102 via any number of approaches.
  • the rotating member 186 may be affixed to the plunger rod guide 170 and/or to the torque spring 180.
  • the void 190c must have a sufficient width (or clearance) denoted as "W” and length denoted as "Li” of engagement to allow for effective damping with less variability than a short, low-clearance interface, which, due to component tolerances and variation, impact damping performance variability.
  • W width
  • Li length
  • the width of the void may be approximately 1mm
  • the length of engagement may be approximately 8mm.
  • the upper frame member 184 may include a dosing feedback component that may provide a visual, audible, haptic, and/or other form of feedback to indicate the status and/or the completion of the dose being administered.
  • the damper mechanism 190 may function according to the following mathematical models prior to impact:
  • the equation for the torque is derived from the theory of Dynamic Viscosity between plates applied on cylinder geometry.
  • damper mechanism 190 may function according to the following mathematical models after impact and during the dosing stage:
  • the equation for the torque is derived from the theory of Dynamic Viscosity between plates applied on cylinder geometry.
  • the equation for the shear stress, ⁇ is derived from the theory of Dynamic Viscosity between plates applied on cylinder geometry. [0057] Accordingly, the damper mechanism 190 creates more damping prior to impact, and relatively less damping during dose delivery.
  • the damper mechanism 190 may be in the form of a deformation region 192 disposed at the end of the plunger rod 162, which deforms as the plunger assembly 160 advances towards the syringe barrel 112. While the deformation region 192 is illustrated as being located near where the plunger rod 162 intersects or couples to the plunger face 164, the deformation region 192 may be any portion or portions of the plunger assembly 160 including on the plunger face 164, itself near a portion where a leading surface of the plunger face contacts the syringe barrel 112, and/or any interface in the axial and/or rotary force loop having a high inertia and kinetic energy.
  • the purpose of the deformation region 192 is to extend impact time, thereby reducing impact forces and stresses in components to reduce and/or avoid failure. So configured, the mass of the plunger face 164 will create a limited and strongly reduced impact shock upon contacting the syringe barrel 112.
  • This deformation region 192 may be constructed from a different material than the remainder of the plunger assembly 160.
  • the deformation region 192 may be constructed from a "softer" or more pliable material that can absorb the impact between the plunger face 164 and the syringe barrel 112.
  • Example materials may include a foam, an elastomer, a crushable honeycomb or 3D lattice structure, etc. So configured, when the plunger rod 162 advances such that the plunger face 164 impacts a portion of the syringe barrel 112 (such as a stopper), the deformation region 192 collapses to dampen the effects of the impact force.
  • the plunger rod 162 may have a deformable retainer coupled thereto to retain the position of the plunger rod 162 within the housing 102.
  • the deformable retainer may slow the plunger rod for a specified number of revolutions (e.g., between 1 and 3 revolutions) before releasing (e.g., breaking). Accordingly, the deformable retainer will dampen the torque or force exerted by the torque spring 180, and will cease to act as a damper upon breaking.
  • the damper mechanism 190 is in the form of a rotating damping device 194.
  • the rotating damping device 194 is disposed under a surface of the cup portion 174 of the plunger rod guide 170.
  • Figs. 5c and 5d illustrate a rotating damping device 194 having an anchor 196 that rocks about a pivot 197 as a central push wheel 198 rotates. As the central push wheel 198 rotates with the plunger rod guide 170, individual splines 198a alternatively contact a first side 196a and a second side 196b of the anchor 196.
  • This rocking motion creates continuously reversing acceleration, which in turn dampens the torque exerted by the torque spring 180.
  • the amount of damping force may be adjusted by altering a rocking angle of the anchor 196, a moment of inertial of the anchor 196, and an angular velocity of the central push wheel 198. As the central push wheel 198 spins faster, the rocking rate of the anchor 196 also increases, which in turn increases the continuously reversing acceleration, thereby providing a greater dampening force.
  • the rotating damping device 194 may be any number of components having relative moving elements such as the plunger rod 162 and the frame member 152.
  • the rotating damping device 194 is in the form of a centrifugal damper assembly that includes a central member 200 and a number of arms 202 that rotate about respective pivots 204.
  • Each of the arms 202 has a weighted portion 206 disposed at distal ends 208 thereof.
  • Each of the arms 202 also include protrusions 210.
  • the inner surface or rim of the cup portion 174 of the plunger rod guide 170 remains fixed relative to the central member 200 and has a number of alternating recesses 212 and protrusions 214. As illustrated in Fig.
  • any number of alternative rotating devices may be used to create a damping force or torque.
  • the mass of the torque spring 180 combined with inertial forces, also provides a dampened motion, as this mass must be accelerated. The resulting acceleration is thereby reduced.
  • the rotating damping device 194 may be a fly wheel damper (not illustrated) that rotates and absorbs energy delivered by the torque spring 180 during initiation and rotation.
  • the plunger rod guide 170 causes the plunger assembly 160 to advance towards the syringe barrel 112, thus urging the medicament through the optional filter mechanism 120 and the needle assembly 114 while the filter mechanism 120 acts to restrict particles disposed within the medicament from passing through the needle assembly 114.
  • the damper mechanism 190 exerts an opposing force on the plunger rod guide 170 and/or any of the moving elements to reduce and/or eliminate any "jerks,” "slaps,” or "bumps".
  • the injector 300 may include any number of features and/or components described with regard to the injector 100 of Figs. l-5g.
  • the injector 300 includes a housing 302 and a torque spring 310 that is guided by a spring guide 320 to improve actuation efficiency and consistency.
  • the spring guide 320 may be in the form of a leaf spring or bridle that is coupled to an outer end 312 of the torque spring 310 to increase torque, assist in unwinding the torque spring 310, reduce hysteresis, and improve cycle life of the torque spring 310. Further, the spring guide may assist with ensuring proper concentric release with the torque spring 310.
  • the spring guide 320 causes the outer end 312 of the torque spring 310 to be pressed outwardly towards the housing 302, which may include any number of guiding protrusions 303.
  • the outer end 312 of the torque spring 310 includes a bent portion 312a.
  • the housing 302 includes a first notch 302a to accommodate the bent portion 312a of the torque spring 310. So configured, because the spring guide 320 exerts an outward force on the outer end 312 of the torque spring 310, the bent portion 312a is retained in the first notch 302a.
  • the spring guide 320 may be coupled to the housing using any number of approaches.
  • an end 320a of the spring guide may include a bent portion 320b that is retained in a second notch 302b of the housing 302.
  • the spring guide 320 may fixed to the housing 302 and/or may be coupled to a post disposed inside or outside of the housing 302. Other examples are possible.
  • the housing 302 may itself act as a spring guide 320' .
  • the housing 302 includes an opening 304.
  • the outer end 312 of the torque spring 310 may pass through the opening 304, and the bent portion 312a of the torque spring 310 may be retained in a third notch 302c.
  • the third notch 302c may be replaced by a second opening (not shown) in which the torque 310 may be threaded therethrough. It is understood that the configuration of the outer end 312 of the torque spring 310 may be modified as needed in order to secure the torque spring to the housing 302 and/or the spring guide 320.
  • the spring guide 320 is coupled and/or constrained to the housing 302 via ribs 302d formed by the housing 302.
  • the torque spring 312 enters a portion the spring guide 320 at a first slot or opening 320d, and exits the spring guide 320 at a second slot or opening 320e.
  • the end 312b of the torque spring 312 is then hooked around a slot or opening 320c in the spring guide 320, thereby eliminating the need for cut outs in the housing 302 which may create weak spots in the housing 302, leading to potential deformation, deflection, and/or the risk of breakage when under high stresses.
  • the above description describes various systems and methods for use with a drug delivery device. It should be clear that the system, drug delivery device or methods can further comprise use of a medicament listed below with the caveat that the following list should neither be considered to be all inclusive nor limiting.
  • the medicament will be contained in a syringe barrel.
  • the syringe barrel is a primary container that is either filled or pre- filled for treatment with the medicament.
  • the primary container can be a cartridge or a pre-filled syringe.
  • the drug delivery device or more specifically the syringe barrel of the device may be filled with colony stimulating factors, such as granulocyte colony-stimulating factor (G-CSF).
  • G-CSF agents include, but are not limited to, Neupogen® (filgrastim) and Neulasta® (pegfilgrastim).
  • the drug delivery device may be used with various pharmaceutical products, such as an erythropoiesis stimulating agent (ESA), which may be in a liquid or a lyophilized form.
  • ESA erythropoiesis stimulating agent
  • An ESA is any molecule that stimulates erythropoiesis, such as Epogen® (epoetin alfa), Aranesp® (darbepoetin alfa), Dynepo® (epoetin delta), Mircera® (methyoxy polyethylene glycol-epoetin beta), Hematide®, MRK-2578, INS-22, Retacrit® (epoetin zeta), Neorecormon® (epoetin beta), Silapo® (epoetin zeta), Binocrit® (epoetin alfa), epoetin alfa Hexal, Abseamed® (epoetin alfa), Ratioepo® (epoetin theta), Eporatio® (epoetin theta), Biopoin® (epoetin theta), epoetin alfa
  • An ESA can be an erythropoiesis stimulating protein.
  • erythropoiesis stimulating protein means any protein that directly or indirectly causes activation of the erythropoietin receptor, for example, by binding to and causing dimerization of the receptor.
  • Erythropoiesis stimulating proteins include erythropoietin and variants, analogs, or derivatives thereof that bind to and activate erythropoietin receptor; antibodies that bind to erythropoietin receptor and activate the receptor; or peptides that bind to and activate erythropoietin receptor.
  • Erythropoiesis stimulating proteins include, but are not limited to, epoetin alfa, epoetin beta, epoetin delta, epoetin omega, epoetin iota, epoetin zeta, and analogs thereof, pegylated erythropoietin, carbamylated erythropoietin, mimetic peptides (including EMP1 /hematide), and mimetic antibodies.
  • Exemplary erythropoiesis stimulating proteins include erythropoietin, darbepoetin, erythropoietin agonist variants, and peptides or antibodies that bind and activate erythropoietin receptor (and include compounds reported in U.S. Publication Nos. 2003/0215444 and 2006/0040858, the disclosures of each of which is incorporated herein by reference in its entirety) as well as erythropoietin molecules or variants or analogs thereof as disclosed in the following patents or patent applications, which are each herein incorporated by reference in its entirety: U.S. Patent Nos.
  • Examples of other pharmaceutical products for use with the device may include, but are not limited to, antibodies such as Vectibix® (panitumumab), XgevaTM (denosumab) and ProliaTM (denosamab); other biological agents such as Enbrel® (etanercept, TNF-receptor /Fc fusion protein, TNF blocker), Neulasta® (pegfilgrastim, pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF), Neupogen® (filgrastim , G-CSF, hu-MetG-CSF), and Nplate® (romiplostim); small molecule drugs such as Sensipar® (cinacalcet).
  • antibodies such as Vectibix® (panitumumab), XgevaTM (denosumab) and ProliaTM (denosamab); other biological agents such as Enbrel® (e
  • the device may also be used with a therapeutic antibody, a polypeptide, a protein or other chemical, such as an iron, for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose.
  • a therapeutic antibody for example, ferumoxytol, iron dextrans, ferric glyconate, and iron sucrose.
  • the pharmaceutical product may be in liquid form, or reconstituted from lyophilized form.
  • proteins include fusions, fragments, analogs, variants or derivatives thereof:
  • OPGL specific antibodies, peptibodies, and related proteins, and the like also referred to as RANKL specific antibodies, peptibodies and the like
  • fully humanized and human OPGL specific antibodies particularly fully humanized monoclonal antibodies, including but not limited to the antibodies described in PCT Publication No.
  • WO 03/002713 which is incorporated herein in its entirety as to OPGL specific antibodies and antibody related proteins, particularly those having the sequences set forth therein, particularly, but not limited to, those denoted therein: 9H7; 18B2; 2D8; 2E11; 16E1; and 22B3, including the OPGL specific antibodies having either the light chain of SEQ ID NO:2 as set forth therein in Figure 2 and/or the heavy chain of SEQ ID NO:4, as set forth therein in Figure 4, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
  • peptibodies of the mTN8-19 family including those of SEQ ID NOS:305-351, including TN8-19-1 through TN8-19-40, TN8-19 conl and TN8-19 con2; peptibodies of the mL2 family of SEQ ID NOS:357-383; the mL15 family of SEQ ID NOS:384-409; the mL17 family of SEQ ID NOS:410-438; the mL20 family of SEQ ID NOS:439-446; the mL21 family of SEQ ID NOS:447-452; the mL24 family of SEQ ID NOS:453-454; and those of SEQ ID
  • IL-4 receptor specific antibodies include those described in PCT Publication No. WO 2005/047331 or PCT Application No. PCT/US2004/37242 and in U.S. Publication No.
  • Ang2 specific antibodies, peptibodies, and related proteins, and the like including but not limited to those described in PCT Publication No. WO 03/057134 and U.S. Publication No. 2003/0229023, each of which is incorporated herein by reference in its entirety particularly in parts pertinent to Ang2 specific antibodies and peptibodies and the like, especially those of sequences described therein and including but not limited to: L1(N); L1(N) WT; L1(N) IK WT; 2xLl(N); 2xLl(N) WT; Con4 (N), Con4 (N) IK WT, 2xCon4 (N) IK; L1C; L1C IK; 2xLlC; Con4C; Con4C IK; 2xCon4C IK; Con4-Ll (N); Con4-LlC; TN-12-9 (N); C17 (N); TN8-8(N); TN8-14 (N); Con 1 (N),
  • WO 2003/030833 which is incorporated herein by reference in its entirety as to the same, particularly Ab526; Ab528; Ab531; Ab533; Ab535; Ab536; Ab537; Ab540; Ab543; Ab544; Ab545; Ab546; A551; Ab553; Ab555; Ab558; Ab559; Ab565;
  • NGF specific antibodies, peptibodies, and related proteins, and the like including, in particular, but not limited to those described in U.S. Publication No. 2005/0074821 and U.S. Patent No. 6,919,426, which are incorporated herein by reference in their entirety particularly as to NGF-specific antibodies and related proteins in this regard, including in particular, but not limited to, the NGF-specific antibodies therein designated 4D4, 4G6, 6H9, 7H2, 14D10 and 14D11, each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication; [0081] CD22 specific antibodies, peptibodies, and related proteins, and the like, such as those described in U.S. Patent No. 5,789,554, which is incorporated herein by reference in its entirety as to CD22 specific antibodies and related proteins, particularly human CD22 specific
  • antibodies such as but not limited to humanized and fully human antibodies, including but not limited to humanized and fully human monoclonal antibodies, particularly including but not limited to human CD22 specific IgG antibodies, such as, for instance, a dimer of a human-mouse monoclonal hLL2 gamma-chain disulfide linked to a human-mouse monoclonal hLL2 kappa- chain, including, but limited to, for example, the human CD22 specific fully humanized antibody in Epratuzumab, CAS registry number 501423-23-0;
  • IGF-1 receptor specific antibodies such as those described in PCT Publication No. WO 06/069202, which is incorporated herein by reference in its entirety as to IGF-1 receptor specific antibodies and related proteins, including but not limited to the IGF-1 specific antibodies therein designated L1H1, L2H2, L3H3, L4H4, L5H5, L6H6, L7H7, L8H8, L9H9, L10H10, L11H11, L12H12, L13H13, L14H14, L15H15, L16H16, L17H17, L18H18, L19H19, L20H20, L21H21, L22H22, L23H23, L24H24, L25H25, L26H26, L27H27, L28H28, L29H29, L30H30, L31H31, L32H32, L33H33, L34H34, L35H35, L36H36, L
  • anti-IGF-lR antibodies for use in the methods and compositions of the present invention are each and all of those described in:
  • B-7 related protein 1 specific antibodies, peptibodies, related proteins and the like (“B7RP-1,” also is referred to in the literature as B7H2, ICOSL, B7h, and CD275), particularly B7RP-specific fully human monoclonal IgG2 antibodies, particularly fully human IgG2 monoclonal antibody that binds an epitope in the first immunoglobulin-like domain of B7RP-1, especially those that inhibit the interaction of B7RP-1 with its natural receptor, ICOS, on activated T cells in particular, especially, in all of the foregoing regards, those disclosed in U.S. Publication No. 2008/0166352 and PCT Publication No.
  • WO 07/011941 which are incorporated herein by reference in their entireties as to such antibodies and related proteins, including but not limited to antibodies designated therein as follow: 16H (having light chain variable and heavy chain variable sequences SEQ ID NO: l and SEQ ID NO:7 respectively therein); 5D (having light chain variable and heavy chain variable sequences SEQ ID NO:2 and SEQ ID NO:9 respectively therein); 2H (having light chain variable and heavy chain variable sequences SEQ ID NO:3 and SEQ ID NO: 10 respectively therein); 43H (having light chain variable and heavy chain variable sequences SEQ ID NO:6 and SEQ ID NO: 14 respectively therein); 41H (having light chain variable and heavy chain variable sequences SEQ ID NO:5 and SEQ ID NO: 13 respectively therein); and 15H (having light chain variable and heavy chain variable sequences SEQ ID NO:4 and SEQ ID NO: 12 respectively therein), each of which is individually and specifically incorporated by reference herein in its entirety fully as disclosed in the foregoing publication;
  • IL-15 specific antibodies, peptibodies, and related proteins, and the like such as, in particular, humanized monoclonal antibodies, particularly antibodies such as those disclosed in U.S. Publication Nos. 2003/0138421; 2003/023586; and 2004/0071702; and U.S. Patent No. 7,153,507, each of which is incorporated herein by reference in its entirety as to IL-15 specific antibodies and related proteins, including peptibodies, including particularly, for instance, but not limited to, HuMax IL-15 antibodies and related proteins, such as, for instance, 146B7;
  • IFN gamma specific antibodies peptibodies, and related proteins and the like, especially human IFN gamma specific antibodies, particularly fully human anti-IFN gamma antibodies, such as, for instance, those described in U.S. Publication No. 2005/0004353, which is incorporated herein by reference in its entirety as to IFN gamma specific antibodies, particularly, for example, the antibodies therein designated 1118; 1118*; 1119; 1121; and 1121*.
  • Specific antibodies include those having the heavy chain of SEQ ID NO: 17 and the light chain of SEQ ID NO: 18; those having the heavy chain variable region of SEQ ID NO:6 and the light chain variable region of SEQ ID NO:8; those having the heavy chain of SEQ ID NO: 19 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO: 10 and the light chain variable region of SEQ ID NO: 12; those having the heavy chain of SEQ ID NO:32 and the light chain of SEQ ID NO:20; those having the heavy chain variable region of SEQ ID NO:30 and the light chain variable region of SEQ ID NO: 12; those having the heavy chain sequence of SEQ ID NO:21 and the light chain sequence of SEQ ID NO:22; those having the heavy chain variable region of SEQ ID NO: 14 and the light chain variable region of SEQ ID NO: 16; those having the heavy chain of SEQ ID NO:21 and the light chain of SEQ ID NO:33; and those having the heavy chain variable region of SEQ ID NO: 14 and the
  • TALL-1 specific antibodies include peptibodies, and the related proteins, and the like, and other TALL specific binding proteins, such as those described in U.S. Publication Nos.
  • PTH Parathyroid hormone
  • TPO-R Thrombopoietin receptor
  • Hepatocyte growth factor (“HGF”) specific antibodies, peptibodies, and related proteins, and the like, including those that target the HGF/SF:cMet axis (HGF/SF:c-Met), such as the fully human monoclonal antibodies that neutralize hepatocyte growth factor/scatter
  • HGF/SF HGF/SF
  • WO 2005/017107 huL2G7 described in U.S. Patent No. 7,220,410 and OA-5d5 described in U.S. Patent Nos. 5,686,292 and 6,468,529 and in PCT Publication No. WO 96/38557, each of which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind HGF;
  • TRAIL-R2 specific antibodies, peptibodies, related proteins and the like, such as those described in U.S. Patent No. 7,521,048, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind TRAIL-R2;
  • TGF-beta specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in U.S. Patent No. 6,803,453 and U.S. Publication No.
  • Amyloid-beta protein specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in PCT Publication No. WO 2006/081171, which is herein incorporated by reference in its entirety, particularly in parts pertinent to proteins that bind amyloid-beta proteins.
  • One antibody contemplated is an antibody having a heavy chain variable region comprising SEQ ID NO:8 and a light chain variable region having SEQ ID NO:6 as disclosed in the foregoing publication;
  • c-Kit specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in U.S. Publication No. 2007/0253951, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind c-Kit and/or other stem cell factor receptors;
  • OX40L specific antibodies, peptibodies, related proteins, and the like including but not limited to those described in U.S. Publication No. 2006/0002929, which is incorporated herein by reference in its entirety, particularly in parts pertinent to proteins that bind OX40L and/or other ligands of the OX40 receptor; and
  • Velcade® (bortezomib); MLN0002 (anti- a4B7 mAb); MLN1202 (anti-CCR2 chemokine receptor mAb); Enbrel® (etanercept, TNF-receptor /Fc fusion protein, TNF blocker); Eprex® (epoetin alfa); Erbitux® (cetuximab, anti-EGFR / HERl / c-ErbB-1); Genotropin® (somatropin, Human Growth Hormone); Herceptin® (trastuzumab, anti-HER2/neu (erbB2) receptor mAb); Humatrope® (somatropin, Human Growth Hormone); Humira® (adalimumab); insulin in solution; Infergen® (interferon alfacon-1); Natrecor® (nesiritide; recombinant human B-type natriuretic peptide (hBNP); Kineret® (
  • LymphoCide® epratuzumab, anti-CD22 mAb
  • BenlystaTM lymphostat B, belimumab, anti- BlyS mAb
  • Metalyse® tenecteplase, t-PA analog
  • Mircera® methoxy polyethylene glycol- epoetin beta
  • Mylotarg® gemtuzumab ozogamicin
  • Raptiva® efalizumab
  • certolizumab pegol, CDP 870 SolirisTM (eculizumab); pexelizumab (anti-C5 complement); Numax® (MEDI-524); Lucentis® (ranibizumab); Panorex® (17-1A, edrecolomab); Trabio® (lerdelimumab); TheraCim hR3 (nimotuzumab); Omnitarg (pertuzumab, 2C4); Osidem® (IDM- 1); OvaRex® (B43.13); Nuvion® (visilizumab); cantuzumab mertansine (huC242-DMl);
  • NeoRecormon® epoetin beta
  • Neumega® oprelvekin, human interleukin-11
  • Neulasta® pegylated filgastrim, pegylated G-CSF, pegylated hu-Met-G-CSF
  • Neupogen® filgrastim , G- CSF, hu-MetG-CSF
  • Orthoclone OKT3® muromonab-CD3, anti-CD3 monoclonal antibody
  • Procrit® epoetin alfa
  • Remicade® infliximab, anti-TNFa monoclonal antibody
  • Reopro® abciximab, anti-GP lib/Ilia receptor monoclonal antibody
  • Actemra® anti-IL6 Receptor mAb
  • Avastin® bevacizumab
  • HuMax-CD4 zanolimumab
  • Rituxan® rituximab,
  • Patent No. 7,153,507 Tysabri® (natalizumab, anti-a4integrin mAb); Valortim® (MDX-1303, anti-B. anthracis protective antigen mAb); ABthraxTM; Vectibix® (panitumumab); Xolair®
  • IL-1 trap the Fc portion of human IgGl and the extracellular domains of both IL- 1 receptor components (the Type I receptor and receptor accessory protein)
  • VEGF trap Ig domains of VEGFR1 fused to IgGl Fc
  • diaclizumab Zenapax® (daclizumab, anti-IL-2Ra mAb); Zevalin® (ibritumomab tiuxetan); Zetia® (ezetimibe); Orencia® (atacicept, TACI-Ig); anti-CD80 monoclonal antibody
  • sclerostin antibody such as but not limited to romosozumab, blosozumab, or BPS 804 (Novartis).
  • therapeutics such as rilotumumab, bixalomer, trebananib, ganitumab, conatumumab, motesanib diphosphate, brodalumab, vidupiprant, panitumumab, denosumab, NPLATE, PROLIA, VECTIBIX or XGEVA.
  • PCSK9 Proprotein Convertase Subtilisin/Kexin Type 9
  • PCSK9 specific antibodies include, but are not limited to, Repatha® (evolocumab) and Praluent® (alirocumab), as well as molecules, variants, analogs or derivatives thereof as disclosed in the following patents or patent applications, each of which is herein incorporated by reference in its entirety for all purposes: U.S. Patent No. 8,030,547, U.S. Publication No. 2013/0064825, WO2008/057457,
  • talimogene laherparepvec or another oncolytic HSV for the treatment of melanoma or other cancers.
  • oncolytic HSV include, but are not limited to talimogene laherparepvec (U.S. Patent Nos. 7,223,593 and 7,537,924); OncoVEXGALV/CD (U.S. Pat. No. 7,981,669); OrienXOlO (Lei et al. (2013), World J. Gastroenterol., 19:5138-5143); G207, 1716; NV1020; NV12023; NV1034 and NV1042 (Vargehes et al. (2002), Cancer Gene Ther., 9(12):967-978).
  • TIMPs are endogenous tissue inhibitors of
  • TIMP-3 is expressed by various cells or and is present in the extracellular matrix; it inhibits all the major cartilage- degrading metalloproteases, and may play a role in role in many degradative diseases of connective tissue, including rheumatoid arthritis and osteoarthritis, as well as in cancer and cardiovascular conditions.
  • the amino acid sequence of TIMP-3, and the nucleic acid sequence of a DNA that encodes TIMP-3, are disclosed in U.S. Patent No. 6,562,596, issued May 13, 2003, the disclosure of which is incorporated by reference herein. Description of TIMP mutations can be found in U.S. Publication No. 2014/0274874 and PCT Publication No. WO 2014/152012.
  • antagonistic antibodies for human calcitonin gene-related peptide (CGRP) receptor and bispecific antibody molecule that target the CGRP receptor and other headache targets. Further information concerning these molecules can be found in PCT
  • bispecific T cell engager (BiTE ® ) antibodies e.g. BLINCYTO ®
  • blindatumomab can be used in the device.
  • an APJ large molecule agonist e.g., apelin or analogues thereof in the device.
  • Information relating to such molecules can be found in PCT Publication No. WO 2014/099984.
  • the medicament comprises a therapeutically effective amount of an anti-thymic stromal lymphopoietin (TSLP) or TSLP receptor antibody.
  • TSLP anti-thymic stromal lymphopoietin
  • anti-TSLP antibodies that may be used in such embodiments include, but are not limited to, those described in U.S. Patent Nos. 7,982,016, and 8,232,372, and U.S. Publication No. 2009/0186022.
  • anti-TSLP receptor antibodies include, but are not limited to, those described in U.S. Patent No. 8,101,182.
  • the medicament comprises a therapeutically effective amount of the anti-TSLP antibody designated as A5 within U.S. Patent No. 7,982,016.

Abstract

Injecteur comprenant un boîtier ayant un ensemble seringue et un mécanisme d'actionnement disposé au moins partiellement dans le boîtier. L'ensemble seringue comprend un corps de seringue qui stocke un médicament à injecter dans un utilisateur, un ensemble aiguille et un élément filtre disposé adjacent à l'ensemble aiguille. Le mécanisme d'actionnement est accouplé de manière fonctionnelle à l'ensemble seringue et comprend un ressort de couple qui exerce un couple pour pousser le médicament à travers l'élément filtre pour être injecté dans l'utilisateur. Le mécanisme d'actionnement comprend en outre un mécanisme d'amortissement qui exerce une force d'opposition pour amortir le mouvement exercé par le ressort de couple.
PCT/US2018/035816 2017-06-08 2018-06-04 Dispositif d'administration de médicament entraîné par couple WO2018226565A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
EP18733474.3A EP3634546A1 (fr) 2017-06-08 2018-06-04 Dispositif d'administration de médicament entraîné par couple
US16/609,466 US11904143B2 (en) 2017-06-08 2018-06-04 Torque driven drug delivery device
JP2019561838A JP7200134B2 (ja) 2017-06-08 2018-06-04 トルク駆動式薬物送達デバイス
CA3066399A CA3066399A1 (fr) 2017-06-08 2018-06-04 Dispositif d'administration de medicament entraine par couple
CN201880036742.6A CN110709121B (zh) 2017-06-08 2018-06-04 扭矩驱动式药物递送装置
MX2019014615A MX2019014615A (es) 2017-06-08 2018-06-04 Dispositivo de administracion de farmacos accionado por par de torsion.
AU2018282077A AU2018282077B2 (en) 2017-06-08 2018-06-04 Torque driven drug delivery device
JP2022202914A JP2023030073A (ja) 2017-06-08 2022-12-20 トルク駆動式薬物送達デバイス
AU2024201097A AU2024201097A1 (en) 2017-06-08 2024-02-20 Torque driven drug delivery device

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762516762P 2017-06-08 2017-06-08
US62/516,762 2017-06-08

Publications (1)

Publication Number Publication Date
WO2018226565A1 true WO2018226565A1 (fr) 2018-12-13

Family

ID=62705752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/035816 WO2018226565A1 (fr) 2017-06-08 2018-06-04 Dispositif d'administration de médicament entraîné par couple

Country Status (8)

Country Link
US (1) US11904143B2 (fr)
EP (1) EP3634546A1 (fr)
JP (2) JP7200134B2 (fr)
CN (1) CN110709121B (fr)
AU (2) AU2018282077B2 (fr)
CA (1) CA3066399A1 (fr)
MX (1) MX2019014615A (fr)
WO (1) WO2018226565A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081479A1 (fr) * 2018-10-15 2020-04-23 Amgen Inc. Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
WO2021163504A1 (fr) 2020-02-13 2021-08-19 Amgen Inc. Formulations d'anticorps anti-tslp humains, et méthodes de traitement de maladie inflammatoire
WO2021168100A1 (fr) 2020-02-18 2021-08-26 Amgen Inc. Formulations d'anticorps anti-tslp humains et leurs procédés d'utilisation
US11311666B1 (en) 2021-02-18 2022-04-26 Fresenius Kabi Deutschland Gmbh Modular wearable medicament delivery device and method of use thereof
US11344682B1 (en) 2021-02-19 2022-05-31 Fresenius Kabi Deutschland Gmbh Drug supply cartridge with visual use indicator and delivery devices that use the same
US11351300B1 (en) 2021-04-30 2022-06-07 Fresenius Kabl Deutschland GmbH Drug dispensing system with replaceable drug supply cartridges
WO2022146931A1 (fr) * 2021-01-03 2022-07-07 Fpin Llc Auto-injecteurs amortis
US11406755B1 (en) 2021-02-19 2022-08-09 Fresenius Kabi Deutschland Gmbh Sensing fluid flow irregularities in an on-body injector
US11413394B1 (en) 2021-02-19 2022-08-16 Fresenius Kabi Deutschland Gmbh Display for wearable drug delivery device
US11419976B1 (en) 2021-04-30 2022-08-23 Fresenius Kabi Deutschland Gmbh Wearable drug delivery device with pressurized fluid dispensing
US11426523B1 (en) 2021-02-19 2022-08-30 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including a removable cartridge
US11464902B1 (en) 2021-02-18 2022-10-11 Fresenius Kabi Deutschland Gmbh Wearable medicament delivery device with compressible reservoir and method of use thereof
WO2022226342A2 (fr) 2021-04-23 2022-10-27 Amgen Inc. Anticorps anti-tslp modifiés
WO2022226339A1 (fr) 2021-04-23 2022-10-27 Amgen Inc. Compositions d'anticorps anti-tslp et leurs utilisations
US11484646B1 (en) 2021-05-04 2022-11-01 Fresenius Kabi Deutschland Gmbh Sealing systems for a reservoir of an on-body injector
US11497847B1 (en) 2021-02-19 2022-11-15 Fresenius Kabi Deutschland Gmbh Wearable injector with adhesive substrate
US11504470B1 (en) 2021-04-30 2022-11-22 Fresenius Kabi Deutschland Gmbh Deformable drug reservoir for wearable drug delivery device
US11529459B1 (en) 2021-04-30 2022-12-20 Fresenius Kabi Deutschland Gmbh Wearable injector with adhesive module
US11607505B1 (en) 2021-02-19 2023-03-21 Fresenius Kabi Deutschland Gmbh Wearable injector with sterility sensors
US11633537B1 (en) 2021-02-19 2023-04-25 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including a pre-filled cartridge
US11717608B1 (en) 2021-05-03 2023-08-08 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including an adhesive pad
US11872369B1 (en) 2021-02-18 2024-01-16 Fresenius Kabi Deutschland Gmbh Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023210670A1 (fr) * 2022-04-26 2023-11-02

Citations (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043335A (en) * 1975-08-23 1977-08-23 Soji Ishikawa Needle holder device of medical administrating injector
US4638809A (en) * 1984-03-22 1987-01-27 Kuperus John H Method of preparing radionuclide doses
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
WO1991005867A1 (fr) 1989-10-13 1991-05-02 Amgen Inc. Isoformes d'erythropoietine
WO1995005465A1 (fr) 1993-08-17 1995-02-23 Amgen Inc. Analogues d'erytropoietine
US5441868A (en) 1983-12-13 1995-08-15 Kirin-Amgen, Inc. Production of recombinant erythropoietin
US5547933A (en) 1983-12-13 1996-08-20 Kirin-Amgen, Inc. Production of erythropoietin
WO1996038557A1 (fr) 1995-06-02 1996-12-05 Genentech, Inc. Antagonistes du recepteur du facteur de croissance des hepatocytes et leurs utilisations
WO1996040772A2 (fr) 1995-06-07 1996-12-19 Ortho Pharmaceutical Corporation Dimeres peptidiques d'agonistes
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5789554A (en) 1994-08-12 1998-08-04 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
WO1999066054A2 (fr) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Fusion analogue d'erythropoietine-albumine serique humaine
US6030086A (en) 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
WO2000024893A2 (fr) 1998-10-23 2000-05-04 Amgen Inc. Methodes et compositions permettant de prevenir et de traiter l'anemie
WO2000061637A1 (fr) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Anticorps du recepteur d'erythropoietine
WO2001031007A2 (fr) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee
WO2001036489A2 (fr) 1999-11-12 2001-05-25 Merck Patent Gmbh Formes d'erythropoietine dotees de proprietes ameliorees
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
WO2001081405A2 (fr) 2000-04-21 2001-11-01 Amgen Inc. Methodes et compositions destinees a la prevention et au traitement de l'anemie
WO2002014356A2 (fr) 2000-08-11 2002-02-21 Baxter Healthcare Sa Methodes therapeutiques de traitement de sujet avec une erytrhopoietine recombinee presentant une activite elevee et peu d'effets secondaires
WO2002020034A1 (fr) 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Ligation chimique 'pseudo'-native
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
WO2002049673A2 (fr) 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugues d'erythropoietine
WO2002085940A2 (fr) 2001-04-04 2002-10-31 Genodyssee Polynucleotides et polypeptides du gene de l'erythropoietine (epo)
WO2003002713A2 (fr) 2001-06-26 2003-01-09 Abgenix, Inc. Anticorps opgl
US20030023586A1 (en) 2000-03-03 2003-01-30 Super Internet Site System Pty Ltd. On-line geographical directory
WO2003029291A2 (fr) 2001-09-25 2003-04-10 F. Hoffmann-La Roche Ag Erythropoietine pegylee et diglycosylee
WO2003030833A2 (fr) 2001-10-11 2003-04-17 Amgen Inc. Agents de liaison spécifiques de l'angiopoïétine-2
US20030082749A1 (en) 2001-08-17 2003-05-01 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US6583272B1 (en) 1999-07-02 2003-06-24 Hoffmann-La Roche Inc. Erythropoietin conjugates
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2003055526A2 (fr) 2001-12-21 2003-07-10 Maxygen Aps Conjugues d'erythropoietine
WO2003057134A2 (fr) 2001-10-11 2003-07-17 Amgen, Inc. Agents de liaison specifiques de l'angiopoietine-2 humaine
US20030138421A1 (en) 2001-08-23 2003-07-24 Van De Winkel Jan G.J. Human Antibodies specific for interleukin 15 (IL-15)
WO2003059951A2 (fr) 2002-01-18 2003-07-24 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
US20030143202A1 (en) 2002-01-31 2003-07-31 Binley Katie (Mary) Anemia
US20030195156A1 (en) 2001-05-11 2003-10-16 Amgen Inc. Peptides and related molecules that bind to TALL-1
WO2003084477A2 (fr) 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
WO2003094858A2 (fr) 2002-05-13 2003-11-20 Modigenetech Ltd. Érythropoïétine comportant une extension ctp
US20030215444A1 (en) 1994-07-26 2003-11-20 Amgen Inc. Antibodies which activate an erythropoietin receptor
US20030235582A1 (en) 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody
WO2004002424A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2004009627A1 (fr) 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
US20040018191A1 (en) 2002-05-24 2004-01-29 Schering Corporation Neutralizing human anti-IGFR antibody
WO2004018667A1 (fr) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha Peptides et medicaments les contenant
WO2004024761A1 (fr) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Polypeptides-has, notamment, erythropoietine-has ayant subi une acylation
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
US20040071702A1 (en) 2001-08-23 2004-04-15 Genmab, Inc. Human antibodies specific for interleukin 15 (IL-15)
WO2004033651A2 (fr) 2002-10-09 2004-04-22 Neose Technologies, Inc. Erythropoietine: remodelage et glycoconjugaison d'erythropoietine
WO2004035603A2 (fr) 2002-10-14 2004-04-29 Abbott Laboratories Anticorps se liant au recepteur de l'erythropoietine
US20040086503A1 (en) 2001-01-05 2004-05-06 Cohen Bruce D. Antibodies to insulin-like growth factor I receptor
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
US20040097712A1 (en) 2002-09-06 2004-05-20 Amgen, Inc. A Corporation Of The State Of Delaware Therapeutic human anti-IL1-R1 monoclonal antibody
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2004058988A2 (fr) 2002-12-20 2004-07-15 Amgen, Inc. Agents de liaison inhibant la myostatine
US20040175379A1 (en) 2002-10-14 2004-09-09 Devries Peter J. Erythropoietin receptor binding antibodies
US6803453B1 (en) 1998-11-27 2004-10-12 Darwin Discovery Ltd. Antibodies associated with alterations in bone density
US20040202655A1 (en) 2003-03-14 2004-10-14 Morton Phillip A. Antibodies to IGF-I receptor for the treatment of cancers
US20040229318A1 (en) 2003-05-17 2004-11-18 George Heavner Erythropoietin conjugate compounds with extended half-lives
US20040228859A1 (en) 2003-04-02 2004-11-18 Yvo Graus Antibodies against insulin-like growth factor 1 receptor and uses thereof
WO2004101606A2 (fr) 2003-05-12 2004-11-25 Affymax, Inc. Nouveaux peptides se fixant au recepteur de l'erythropoietine
WO2004101611A2 (fr) 2003-05-12 2004-11-25 Affymax, Inc. Nouveaux peptides se fixant au recepteur de l'erythropoietine
WO2004101600A2 (fr) 2003-05-12 2004-11-25 Affymax, Inc. Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
US6835809B1 (en) 1998-10-23 2004-12-28 Amgen Inc. Thrombopoietic compounds
US20040266690A1 (en) 2003-05-30 2004-12-30 Chadler Pool Formation of novel erythropoietin conjugates using transglutaminase
US20040265307A1 (en) 2002-06-14 2004-12-30 Immunogen Inc. Anti-IGF-I receptor antibody
US20050004353A1 (en) 2002-10-16 2005-01-06 Amgen, Inc., A Corporation Of The State Of Delaware Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
WO2005001136A1 (fr) 2003-06-04 2005-01-06 Irm Llc Methodes et compositions pour la modulation de l'expression de l'erythropoietine
WO2005001025A2 (fr) 2003-05-06 2005-01-06 Syntonix Pharmaceuticals, Inc. Hybrides monomeres/dimeres chimeriques d'immunoglobuline
US20050008642A1 (en) 2003-07-10 2005-01-13 Yvo Graus Antibodies against insulin-like growth factor 1 receptor and uses thereof
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
US20050026834A1 (en) 1999-01-14 2005-02-03 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
WO2005016970A2 (fr) 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
WO2005017107A2 (fr) 2003-07-18 2005-02-24 Amgen Inc. Agents de liaison specifiques se liant a un facteur de croissance hepatocyte
WO2005021579A2 (fr) 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Peptides mimetiques epo et proteines de fusion
WO2005025606A1 (fr) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
US20050074821A1 (en) 2003-07-15 2005-04-07 Wild Kenneth D. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
WO2005032460A2 (fr) 2003-09-30 2005-04-14 Centocor, Inc. Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes
US20050084906A1 (en) 2002-01-18 2005-04-21 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US20050096461A1 (en) 1997-07-14 2005-05-05 Bolder Biotechnology, Inc. Cysteine variants of erythropoietin
WO2005047331A2 (fr) 2003-11-07 2005-05-26 Immunex Corporation Anticorps liant un recepteur de l'interleucine 4
US20050124564A1 (en) 2002-01-31 2005-06-09 Binley Katie M. Anemia
WO2005051327A2 (fr) 2003-11-24 2005-06-09 Neose Technologies, Inc. Erythropoietine glycopegylee
US20050136063A1 (en) 2003-11-21 2005-06-23 Schering Corporation Anti-IGFR antibody therapeutic combinations
WO2005058967A2 (fr) 2003-12-16 2005-06-30 Pierre Fabre Medicament Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
WO2005063808A1 (fr) 2003-12-31 2005-07-14 Merck Patent Gmbh Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
US20050153879A1 (en) 2002-03-26 2005-07-14 Monica Svetina Process for the preparation of a desired erythropoietin glyco-isoform profile
WO2005063809A1 (fr) 2003-12-22 2005-07-14 Dubai Genetics Fz-Llc Erythopoietine identique a la forme naturelle
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20050158822A1 (en) 2004-01-20 2005-07-21 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
WO2005070451A1 (fr) 2004-01-22 2005-08-04 Zafena Aktiebolag Composition pharmaceutique comprenant une erythropoietine non glycosylee
US20050170457A1 (en) 2003-12-31 2005-08-04 Chadler Pool Novel recombinant proteins with N-terminal free thiol
US20050181359A1 (en) 1999-04-15 2005-08-18 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
WO2005081687A2 (fr) 2003-09-30 2005-09-09 Centocor, Inc. Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005084711A1 (fr) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products Erythropoietine recombinante pegylee a activite in vivo
WO2005092369A2 (fr) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugues d'hydroxy-ethyl-amidon et d'erythropoietine
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
WO2005103076A2 (fr) 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Variants d'erythropoietine
US20060002929A1 (en) 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
WO2006002646A2 (fr) 2004-07-07 2006-01-12 H. Lundbeck A/S Nouvelle erythropoietine carbamylee et son procede de production
WO2006013472A2 (fr) 2004-07-29 2006-02-09 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et utilisations
US20060040358A1 (en) 1998-12-03 2006-02-23 Tanja Ligensa IGF-1 receptor interacting proteins
WO2006029094A2 (fr) 2004-09-02 2006-03-16 Xencor, Inc. Derives d'erythropoietine a antigenicite modifiee
WO2006050959A2 (fr) 2004-11-10 2006-05-18 Aplagen Gmbh Molecules favorisant l'hematopoiese
US20060111279A1 (en) 2003-11-24 2006-05-25 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2006069202A2 (fr) 2004-12-22 2006-06-29 Amgen Inc. Compositions et procedes impliquant des anticorps diriges contre le recepteur igf-1r
WO2006081171A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
WO2006138729A2 (fr) 2005-06-17 2006-12-28 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2007000328A1 (fr) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
WO2007011941A2 (fr) 2005-07-18 2007-01-25 Amgen Inc. Anticorps neutralisants anti-b7rp1 humains
WO2007012614A2 (fr) 2005-07-22 2007-02-01 Pierre Fabre Medicament Nouveaux anticorps anti igf-ir et leur utilisation
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US20070110747A1 (en) 2005-05-03 2007-05-17 Ucb S.A. Binding agents
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US7271689B1 (en) 2000-11-22 2007-09-18 Fonar Corporation Magnet structure
US20070253951A1 (en) 2006-04-24 2007-11-01 Gordon Ng Humanized c-Kit antibody
WO2007136752A2 (fr) 2006-05-19 2007-11-29 Glycofi, Inc. Compositions d'érythropoïétine
WO2008057459A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057458A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008125623A2 (fr) 2007-04-13 2008-10-23 Novartis Ag Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
WO2008133647A2 (fr) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonistes de pcsk9
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies
WO2009055783A2 (fr) 2007-10-26 2009-04-30 Schering Corporation Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol
US20090186022A1 (en) 2006-02-23 2009-07-23 Novartis Ag Organic Compounds
WO2009100318A1 (fr) 2008-02-07 2009-08-13 Merck & Co., Inc. Antagonistes de 1b20 pcsk9
WO2009100297A1 (fr) 2008-02-07 2009-08-13 Merck & Co., Inc. Antagonistes de pcsk9 1d05
US20090234106A1 (en) 2006-09-08 2009-09-17 Amgen Inc. Anti-activin a antibodies and uses thereof
WO2010029513A2 (fr) 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Antagonistes de pcsk9
WO2010075238A1 (fr) 2008-12-23 2010-07-01 Amgen Inc. Protéines de liaison au récepteur cgrp humain
WO2010077854A1 (fr) 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. Anticorps humains à grande affinité contre pcsk9
WO2011037791A1 (fr) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonistes de pcsk9
WO2011053783A2 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes et variants ax213 et ax132 pcsk9
WO2011053759A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes
WO2011072263A1 (fr) 2009-12-11 2011-06-16 Irm Llc Antagonistes de pcsk9
US7981669B2 (en) 2003-07-25 2011-07-19 Biovex Limited Viral vectors
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2011111007A2 (fr) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation Anticorps présentant une liaison à l'antigène dépendante du ph
US8030547B2 (en) 2002-03-29 2011-10-04 Kumiai Chemical Industry Co., Ltd. Gene coding for acetolactate synthase
US8101182B2 (en) 2007-06-20 2012-01-24 Novartis Ag Methods and compositions for treating allergic diseases
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (fr) 2010-12-22 2012-06-28 Genentech, Inc. Anticorps anti-pcsk9 et procédés d'utilisation
US8232372B2 (en) 2006-12-14 2012-07-31 Schering Corp. Engineered anti-TSLP antibody
WO2012101251A1 (fr) 2011-01-28 2012-08-02 Sanofi Anticorps humains dirigés contre la pcsk9 destinés à être utilisés dans des procédés de traitement basés sur des schémas posologiques particuliers
WO2012109530A1 (fr) 2011-02-11 2012-08-16 Irm Llc Antagonistes de pcsk9
US20130064825A1 (en) 2011-05-10 2013-03-14 Amgen Inc. Methods of treating or preventing cholesterol related disorders
US20130072880A1 (en) * 2011-09-16 2013-03-21 Tyco Healthcare Group Lp Fluid Delivery Device with Filtration
WO2014099984A1 (fr) 2012-12-20 2014-06-26 Amgen Inc. Agonistes du récepteur apj et leurs utilisations
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
WO2014152012A2 (fr) 2013-03-14 2014-09-25 Amgen Inc. Variants d'inhibiteur tissulaire de la métalloprotéinase type iii (timp-3), compositions et procédés
US20150314076A1 (en) * 2005-01-21 2015-11-05 Novo Nordisk A/S Automatic Injection Device with a Top Release Mechanism
US20150320938A1 (en) * 2014-05-06 2015-11-12 Biomet Biologics, Llc Single Step Desiccating Bead-in-Syringe Concentrating Device

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5533964A (en) 1994-02-17 1996-07-09 Rossmark Medical Publishers Inc. Apparatus for removal of excess hydrogen ions from humans
SE505274C2 (sv) 1995-10-24 1997-07-28 Sten Andersson Användning av en hydrofob zeolit för avlägsnande av för injektionslösningar i läkemedelssammanhang använda konserveringsmedel från en proteinlösning
US5807344A (en) 1997-02-10 1998-09-15 In-X Corporation Arterial blood gas syringe including filter member
US20020119417A1 (en) 1998-05-29 2002-08-29 Arthur Ashman Nozzle tip for use with syringe and method for using same
US6554803B1 (en) 1997-04-02 2003-04-29 Arthur Ashman Combination syringe and aspirator for bone regeneration material and method for using the syringe
DE19821933C1 (de) 1998-05-15 1999-11-11 Disetronic Licensing Ag Vorrichtung zur Verabreichung eines injizierbaren Produkts
SE9803662D0 (sv) 1998-10-26 1998-10-26 Pharmacia & Upjohn Ab Autoinjector
GB2344526B (en) * 1999-01-12 2001-05-23 Dumaresq Lucas Alison Jayne Syringe with filter,and filter therefor
ES2251371T3 (es) 1999-04-16 2006-05-01 Becton Dickinson And Company Inyector de tipo pluma con caracteristicas de combinacion de sustancias automatizada.
GB0011443D0 (en) 2000-05-13 2000-06-28 Dna Research Instr Limited Separation device
DE10046279A1 (de) 2000-09-19 2002-04-04 Disetronic Licensing Ag Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts
US6770052B2 (en) 2000-10-10 2004-08-03 Meridian Medical Technologies, Inc. Wet/dry automatic injector assembly
US6899699B2 (en) 2001-01-05 2005-05-31 Novo Nordisk A/S Automatic injection device with reset feature
SE0102922D0 (sv) 2001-08-31 2001-08-31 Astrazeneca Ab Method and apparatus for sample preparation
GB0125506D0 (en) 2001-10-24 2001-12-12 Weston Medical Ltd Needle free injection method and apparatus
DE10226537A1 (de) 2002-06-14 2004-01-08 Peter Eichhorst Preinjektionseinrichtung
DE10240166A1 (de) 2002-08-30 2004-03-18 Disetronic Licensing Ag Vorrichtung zur kontrollierten Ausschüttung einer injizierbaren Flüssigkeit
US9486581B2 (en) 2002-09-11 2016-11-08 Becton, Dickinson And Company Injector device with force lock-out and injection rate limiting mechanisms
US6939319B1 (en) 2002-11-20 2005-09-06 Conrad Anstead Process and device for single use, needle-free intradermal, subcutaneous, or intramuscular injections
US20040158226A1 (en) 2003-02-07 2004-08-12 Genoptix, Inc. Syringe tissue sieve
IL157981A (en) 2003-09-17 2014-01-30 Elcam Medical Agricultural Cooperative Ass Ltd Auto injector
JP4406344B2 (ja) 2004-09-27 2010-01-27 富士フイルム株式会社 多孔質膜カートリッジ及びその製造方法
ES2334808T3 (es) 2004-10-21 2010-03-16 Novo Nordisk A/S Dispositivo de inyeccion con resorte de torsion con indicacion visual rotativa.
US20070265568A1 (en) 2004-11-04 2007-11-15 Izrail Tsals Automatic Injector
DE102004063647A1 (de) 2004-12-31 2006-07-20 Tecpharma Licensing Ag Vorrichtung zur dosierten Verabreichung eines fluiden Produkts mit Kupplung
ES2716135T5 (es) 2005-01-24 2023-06-15 Antares Pharma Inc Inyector de chorro asistido por aguja con jeringa precargada
US20060276753A1 (en) 2005-06-01 2006-12-07 Victor Kronestedt Device for delivering medicament
JP5026412B2 (ja) 2005-06-01 2012-09-12 エスエイチエル グループ エービー 薬物送達装置
US7896850B2 (en) 2005-06-01 2011-03-01 Telefonaktiebolaget L M Ericsson (Publ) Device for delivering medicament
DE102005025424A1 (de) 2005-06-02 2006-12-07 Tecpharma Licensing Ag Injektionsvorrichtung mit einem Drehfederantrieb
GB0524604D0 (en) 2005-12-02 2006-01-11 Owen Mumford Ltd Injection method and apparatus
KR100738100B1 (ko) 2006-01-19 2007-07-12 삼성전자주식회사 액체 시편의 예비 처리 및 주입 장치 및 방법
RU2408392C2 (ru) 2006-08-18 2011-01-10 Схл Груп Аб Устройство для доставки лекарственного средства, включающее механизм сброса давления
JP2010503430A (ja) 2006-09-15 2010-02-04 テクファーマ・ライセンシング・アクチェンゲゼルシャフト 低損失駆動部を備える注射装置
MX2009009494A (es) * 2007-03-09 2009-09-15 Lilly Co Eli Mecanismo de retardo para dispositivo de inyeccion automatica.
DK2192938T3 (en) 2007-09-18 2018-01-02 Shl Group Ab AUTOMATIC INJECTION DEVICE WITH NEEDLES
WO2009042993A1 (fr) 2007-09-28 2009-04-02 Flodesign, Inc. Filtre pour améliorations de flux pour la distribution de biomatériaux
GB0802351D0 (en) 2008-02-08 2008-03-12 Owen Mumford Ltd Injection devices
DE102008011885A1 (de) 2008-02-29 2009-09-10 Tecpharma Licensing Ag Doppelfunktionsfeder
DE102008011881A1 (de) * 2008-02-29 2009-09-10 Tecpharma Licensing Ag Leerschießgeschwindigkeitsbegrenzungsbremse
WO2010014033A1 (fr) 2008-07-31 2010-02-04 Ge Healthcare Bio-Sciences Ab Dispositif de séparation
DK3017837T3 (en) 2008-10-29 2017-04-10 Shl Group Ab INJECTION DEVICE
GB0821492D0 (en) 2008-11-25 2008-12-31 Team Holdings Uk Ltd Integrated auto-injector cartridge system
EP2198903A1 (fr) 2008-12-19 2010-06-23 Sanofi-Aventis Deutschland GmbH Mécanisme à moteur pour dispositif d'administration de médicaments et dispositif d'administration de médicaments
ATE520432T1 (de) 2009-02-11 2011-09-15 Nils Leuzinger Injektionsvorrichtung mit druckdämpfung für die injektion eines fluids
DE202009001836U1 (de) 2009-02-13 2009-05-20 Dieter Hölzle Technik-Projekte GmbH Elektromechanische Injektionsvorrichtung
GB0918145D0 (en) 2009-10-16 2009-12-02 Owen Mumford Ltd Injector apparatus
CN102762243B (zh) 2009-12-14 2014-07-23 Shl集团有限责任公司 药物传输设备
EP2364740A1 (fr) 2010-03-09 2011-09-14 Sanofi-Aventis Deutschland GmbH Agencement pour transférer une translation de moyen de commande à un piston
EP2364739A1 (fr) 2010-03-09 2011-09-14 Sanofi-Aventis Deutschland GmbH Auto-injecteur réutilisable
EP2364741A1 (fr) 2010-03-09 2011-09-14 Sanofi-Aventis Deutschland GmbH Mécanisme d'interverrouillage pour la définition d'une séquence d'opération d'un auto-injecteur
US9095657B2 (en) 2010-04-19 2015-08-04 Shl Group Ab Self-administration medicament delivery device
EP2563431A4 (fr) 2010-04-26 2017-11-29 SHL Group AB Dispositif d'administration de médicament
EP2399631A1 (fr) * 2010-06-28 2011-12-28 Sanofi-Aventis Deutschland GmbH Auto-injecteur avec élément d'amortissement d'injection
EP2399627A1 (fr) 2010-06-28 2011-12-28 Sanofi-Aventis Deutschland GmbH Auto-injecteur
GB201015799D0 (en) 2010-09-21 2010-10-27 Owen Mumford Ltd Autoinjectors
EP2438939A1 (fr) 2010-10-08 2012-04-11 Sanofi-Aventis Deutschland GmbH Agencement pour coupler un piston avec une seringue ou un butoir
EP2468341A1 (fr) 2010-12-21 2012-06-27 Sanofi-Aventis Deutschland GmbH Auto-injecteur
EP2468337A1 (fr) 2010-12-21 2012-06-27 Sanofi-Aventis Deutschland GmbH Dispositif secondaire pour auto-injecteur et auto-injecteur
GB2487235A (en) 2011-01-17 2012-07-18 Owen Mumford Ltd Injection device with pneumatic damping of the drive mechanism
CN107096098A (zh) 2011-04-21 2017-08-29 艾伯维公司 可佩戴式自动注射装置
US8834449B2 (en) 2012-01-23 2014-09-16 Ikomed Technologies, Inc. Mixing syringe
US9751056B2 (en) 2012-01-23 2017-09-05 Merit Medical Systems, Inc. Mixing syringe
US20130230841A1 (en) 2012-03-02 2013-09-05 Toluna Usa, Inc. Respondent Selection for Surveys
WO2013135566A2 (fr) 2012-03-14 2013-09-19 Carebay Europe Ltd Dispositif d'administration de médicament
CN104168936B (zh) 2012-03-16 2016-07-06 卡贝欧洲有限公司 药剂输送装置
US9834809B2 (en) 2014-02-28 2017-12-05 Lockheed Martin Corporation Syringe for obtaining nano-sized materials for selective assays and related methods of use
AU2013269824B2 (en) 2012-05-31 2015-12-24 Carebay Europe Ltd Medicament delivery device
WO2014001319A1 (fr) 2012-06-29 2014-01-03 Novo Nordisk A/S Dispositif d'injection à ressort
EP2716316A1 (fr) 2012-10-04 2014-04-09 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicament avec mécanisme d'amortissement
EP2906271B1 (fr) 2012-10-15 2018-03-28 Novo Nordisk A/S Dispositif d'injection entraîné par ressort
KR101354451B1 (ko) 2012-12-03 2014-01-28 김근배 필터 주사기
US8591463B1 (en) 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
BR112015020017A2 (pt) 2013-03-14 2017-07-18 Lilly Co Eli mecanismo de retardo apropriado para um dispositivo de injeção automático compacto
EP2781230B1 (fr) 2013-03-22 2019-08-21 TecPharma Licensing AG Dispositif de distribution de substances avec dispositif de signal
MX2015014288A (es) 2013-04-10 2016-01-20 Sanofi Sa Dispositivo de inyeccion.
JP6546154B2 (ja) 2013-04-10 2019-07-17 サノフイＳａｎｏｆｉ 注射デバイス
JP6404323B2 (ja) 2013-04-10 2018-10-10 サノフイＳａｎｏｆｉ 注射デバイス
BR112015024154A2 (pt) 2013-04-10 2017-07-18 Sanofi Sa mecanismo de controle de velocidade de dispensação e dispositivo de injeção
CN105102025A (zh) 2013-04-10 2015-11-25 赛诺菲 注射装置和装配方法
TW201507750A (zh) 2013-04-10 2015-03-01 Sanofi Sa 注射裝置（一）
JP6348170B2 (ja) 2013-04-18 2018-06-27 ノボ・ノルデイスク・エー／エス ねじりばねの固定
EP2986335B1 (fr) 2013-04-19 2018-08-15 Novo Nordisk A/S Dispositif d'administration de médicament avec unité d'alimentation compacte
AU2014259005B2 (en) 2013-04-23 2019-01-03 E3D Agricultural Cooperative Association Ltd. Automatic injection device for administration of high viscosity medication
CN105263545A (zh) 2013-06-03 2016-01-20 诺和诺德股份有限公司 医用注射装置
EP3021897B1 (fr) 2013-07-17 2017-05-17 Sanofi Mécanisme dýentraînement
TWI569841B (zh) 2013-10-10 2017-02-11 卡貝歐洲有限公司 藥物輸送裝置
JP6611708B2 (ja) 2013-10-16 2019-11-27 ノボ・ノルデイスク・エー／エス ブレーキ機構を有する薬物送達デバイス
CN105705181A (zh) 2013-11-15 2016-06-22 卡贝欧洲有限公司 药剂输送装置
US20150165128A1 (en) 2013-12-17 2015-06-18 Sang-A Frontec Co., Ltd. Syringe
US10159916B2 (en) 2013-12-18 2018-12-25 Ge Healthcare Uk Limited Syringe filter
TWI552781B (zh) 2014-09-30 2016-10-11 Liquid suction and discharge filter
EP3064241A1 (fr) 2015-03-06 2016-09-07 Carebay Europe Ltd. Mécanisme d'alimentation électrique
CN106492313B (zh) * 2016-12-27 2023-01-10 甘肃成纪生物药业有限公司 一种卡式全自动注射笔

Patent Citations (208)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043335A (en) * 1975-08-23 1977-08-23 Soji Ishikawa Needle holder device of medical administrating injector
US5756349A (en) 1983-12-13 1998-05-26 Amgen Inc. Production of erythropoietin
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US5955422A (en) 1983-12-13 1999-09-21 Kirin-Amgen, Inc. Production of erthropoietin
US5441868A (en) 1983-12-13 1995-08-15 Kirin-Amgen, Inc. Production of recombinant erythropoietin
US5547933A (en) 1983-12-13 1996-08-20 Kirin-Amgen, Inc. Production of erythropoietin
US5618698A (en) 1983-12-13 1997-04-08 Kirin-Amgen, Inc. Production of erythropoietin
US5621080A (en) 1983-12-13 1997-04-15 Kirin-Amgen, Inc. Production of erythropoietin
US4638809A (en) * 1984-03-22 1987-01-27 Kuperus John H Method of preparing radionuclide doses
WO1991005867A1 (fr) 1989-10-13 1991-05-02 Amgen Inc. Isoformes d'erythropoietine
US7217689B1 (en) 1989-10-13 2007-05-15 Amgen Inc. Glycosylation analogs of erythropoietin
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
WO1995005465A1 (fr) 1993-08-17 1995-02-23 Amgen Inc. Analogues d'erytropoietine
US6562596B1 (en) 1993-10-06 2003-05-13 Amgen Inc. Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5986047A (en) 1993-11-19 1999-11-16 Affymax Technologies N.V. Peptides that bind to the erythropoietin receptor
US20030215444A1 (en) 1994-07-26 2003-11-20 Amgen Inc. Antibodies which activate an erythropoietin receptor
US5789554A (en) 1994-08-12 1998-08-04 Immunomedics, Inc. Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells
WO1996038557A1 (fr) 1995-06-02 1996-12-05 Genentech, Inc. Antagonistes du recepteur du facteur de croissance des hepatocytes et leurs utilisations
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6468529B1 (en) 1995-06-02 2002-10-22 Genentech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
WO1996040772A2 (fr) 1995-06-07 1996-12-19 Ortho Pharmaceutical Corporation Dimeres peptidiques d'agonistes
US20050096461A1 (en) 1997-07-14 2005-05-05 Bolder Biotechnology, Inc. Cysteine variants of erythropoietin
US20050107591A1 (en) 1997-07-14 2005-05-19 Bolder Biotechnology, Inc. Cysteine variants of erythropoietin
US6391633B1 (en) 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6030086A (en) 1998-03-02 2000-02-29 Becton, Dickinson And Company Flash tube reflector with arc guide
US20040248815A1 (en) 1998-04-20 2004-12-09 Ortho Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
US6310078B1 (en) 1998-04-20 2001-10-30 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
US6750369B2 (en) 1998-04-20 2004-06-15 Ortho Mcneil Pharmaceutical, Inc. Substituted amino acids as erythropoietin mimetics
WO1999066054A2 (fr) 1998-06-15 1999-12-23 Genzyme Transgenics Corp. Fusion analogue d'erythropoietine-albumine serique humaine
US20040143857A1 (en) 1998-06-15 2004-07-22 Michael Young Erythropoietin analog-human serum albumin fusion
US20020155998A1 (en) 1998-06-15 2002-10-24 Genzyme Transgenics Corporation, A Massachusetts Corporation Erythropoietin analog-human serum albumin fusion
US20050158832A1 (en) 1998-06-15 2005-07-21 Michael Young Erythropoietin analog-human serum albumin fusion
US6835809B1 (en) 1998-10-23 2004-12-28 Amgen Inc. Thrombopoietic compounds
WO2000024893A2 (fr) 1998-10-23 2000-05-04 Amgen Inc. Methodes et compositions permettant de prevenir et de traiter l'anemie
US6803453B1 (en) 1998-11-27 2004-10-12 Darwin Discovery Ltd. Antibodies associated with alterations in bone density
US20060040358A1 (en) 1998-12-03 2006-02-23 Tanja Ligensa IGF-1 receptor interacting proteins
US20050026834A1 (en) 1999-01-14 2005-02-03 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20050244409A1 (en) 1999-04-14 2005-11-03 Smithkline Beecham Corporation Erythropoietin receptor antibodies
WO2000061637A1 (fr) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Anticorps du recepteur d'erythropoietine
US20050181359A1 (en) 1999-04-15 2005-08-18 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6583272B1 (en) 1999-07-02 2003-06-24 Hoffmann-La Roche Inc. Erythropoietin conjugates
WO2001031007A2 (fr) 1999-10-22 2001-05-03 Millennium Pharmaceuticals, Inc. Molecules d'acide nucleique derivees d'un cerveau de rat et modeles de mort cellulaire programmee
US20050202538A1 (en) 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2001036489A2 (fr) 1999-11-12 2001-05-25 Merck Patent Gmbh Formes d'erythropoietine dotees de proprietes ameliorees
US7223593B2 (en) 2000-01-21 2007-05-29 Biovex Limited Herpes virus strains for gene therapy
US7537924B2 (en) 2000-01-21 2009-05-26 Biovex Limited Virus strains
US20030023586A1 (en) 2000-03-03 2003-01-30 Super Internet Site System Pty Ltd. On-line geographical directory
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
WO2001081405A2 (fr) 2000-04-21 2001-11-01 Amgen Inc. Methodes et compositions destinees a la prevention et au traitement de l'anemie
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
WO2002014356A2 (fr) 2000-08-11 2002-02-21 Baxter Healthcare Sa Methodes therapeutiques de traitement de sujet avec une erytrhopoietine recombinee presentant une activite elevee et peu d'effets secondaires
WO2002020034A1 (fr) 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Ligation chimique 'pseudo'-native
WO2002019963A2 (fr) 2000-09-08 2002-03-14 Gryphon Therapeutics, Inc. Protéines de synthèse stimulant l'érythropoïèse
US7271689B1 (en) 2000-11-22 2007-09-18 Fonar Corporation Magnet structure
WO2002049673A2 (fr) 2000-12-20 2002-06-27 F. Hoffmann-La Roche Ag Conjugues d'erythropoietine
US20040086503A1 (en) 2001-01-05 2004-05-06 Cohen Bruce D. Antibodies to insulin-like growth factor I receptor
US20050244408A1 (en) 2001-01-05 2005-11-03 Cohen Bruce D Antibodies to insulin-like growth factor I receptor
US7037498B2 (en) 2001-01-05 2006-05-02 Abgenix, Inc. Antibodies to insulin-like growth factor I receptor
WO2002085940A2 (fr) 2001-04-04 2002-10-31 Genodyssee Polynucleotides et polypeptides du gene de l'erythropoietine (epo)
US20030195156A1 (en) 2001-05-11 2003-10-16 Amgen Inc. Peptides and related molecules that bind to TALL-1
US20060135431A1 (en) 2001-05-11 2006-06-22 Amgen Inc. Peptides and related molecules that bind to TALL-1
WO2003002713A2 (fr) 2001-06-26 2003-01-09 Abgenix, Inc. Anticorps opgl
US7030226B2 (en) 2001-08-17 2006-04-18 Sun Lee-Hwei K Fc fusion proteins of human erythropoietin with increased biological activities
US20050142642A1 (en) 2001-08-17 2005-06-30 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20040175824A1 (en) 2001-08-17 2004-09-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with high biological activities
US20050124045A1 (en) 2001-08-17 2005-06-09 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US20030082749A1 (en) 2001-08-17 2003-05-01 Sun Lee-Hwei K. Fc fusion proteins of human erythropoietin with increased biological activities
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20040071702A1 (en) 2001-08-23 2004-04-15 Genmab, Inc. Human antibodies specific for interleukin 15 (IL-15)
US20030138421A1 (en) 2001-08-23 2003-07-24 Van De Winkel Jan G.J. Human Antibodies specific for interleukin 15 (IL-15)
US7153507B2 (en) 2001-08-23 2006-12-26 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
WO2003029291A2 (fr) 2001-09-25 2003-04-10 F. Hoffmann-La Roche Ag Erythropoietine pegylee et diglycosylee
US20030077753A1 (en) 2001-09-25 2003-04-24 Wilhelm Tischer Diglycosylated erythropoietin
US20060088906A1 (en) 2001-10-10 2006-04-27 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US20030229023A1 (en) 2001-10-11 2003-12-11 Oliner Jonathan Daniel Specific binding agents of human angiopoietin-2
WO2003030833A2 (fr) 2001-10-11 2003-04-17 Amgen Inc. Agents de liaison spécifiques de l'angiopoïétine-2
WO2003057134A2 (fr) 2001-10-11 2003-07-17 Amgen, Inc. Agents de liaison specifiques de l'angiopoietine-2 humaine
WO2003055526A2 (fr) 2001-12-21 2003-07-10 Maxygen Aps Conjugues d'erythropoietine
WO2003059951A2 (fr) 2002-01-18 2003-07-24 Pierre Fabre Medicament Anticorps anti-igf-ir et leurs applications
US20050084906A1 (en) 2002-01-18 2005-04-21 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US20050124564A1 (en) 2002-01-31 2005-06-09 Binley Katie M. Anemia
US20030143202A1 (en) 2002-01-31 2003-07-31 Binley Katie (Mary) Anemia
US20050153879A1 (en) 2002-03-26 2005-07-14 Monica Svetina Process for the preparation of a desired erythropoietin glyco-isoform profile
WO2003084477A2 (fr) 2002-03-29 2003-10-16 Centocor, Inc. Corps mimetiques de cdr de mammifere, compositions, procedes et utilisations
US8030547B2 (en) 2002-03-29 2011-10-04 Kumiai Chemical Industry Co., Ltd. Gene coding for acetolactate synthase
WO2003094858A2 (fr) 2002-05-13 2003-11-20 Modigenetech Ltd. Érythropoïétine comportant une extension ctp
US20040009902A1 (en) 2002-05-13 2004-01-15 Irving Boime CTP extended erythropoietin
US20040018191A1 (en) 2002-05-24 2004-01-29 Schering Corporation Neutralizing human anti-IGFR antibody
US20050186203A1 (en) 2002-06-14 2005-08-25 Immunogen Inc. Anti-IGF-I receptor antibody
US20050249728A1 (en) 2002-06-14 2005-11-10 Immunogen Inc. Anti-IGF-I receptor antibody
US20040265307A1 (en) 2002-06-14 2004-12-30 Immunogen Inc. Anti-IGF-I receptor antibody
US20030235582A1 (en) 2002-06-14 2003-12-25 Immunogen, Inc. Anti-IGF-I receptor antibody
WO2004002424A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques d'epo de mammifere a deletion ch1, compositions, methodes et utilisations associees
WO2004002417A2 (fr) 2002-06-28 2004-01-08 Centocor, Inc. Corps mimetiques mammaliens a deletion ch1, compositions, procedes et utilisations
WO2004009627A1 (fr) 2002-07-19 2004-01-29 Cangene Corporation Composes erythropoietiques pegyles
WO2004018667A1 (fr) 2002-08-26 2004-03-04 Kirin Beer Kabushiki Kaisha Peptides et medicaments les contenant
US20040097712A1 (en) 2002-09-06 2004-05-20 Amgen, Inc. A Corporation Of The State Of Delaware Therapeutic human anti-IL1-R1 monoclonal antibody
WO2004024761A1 (fr) 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh Polypeptides-has, notamment, erythropoietine-has ayant subi une acylation
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
WO2004033651A2 (fr) 2002-10-09 2004-04-22 Neose Technologies, Inc. Erythropoietine: remodelage et glycoconjugaison d'erythropoietine
US20040175379A1 (en) 2002-10-14 2004-09-09 Devries Peter J. Erythropoietin receptor binding antibodies
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
WO2004035603A2 (fr) 2002-10-14 2004-04-29 Abbott Laboratories Anticorps se liant au recepteur de l'erythropoietine
US20050004353A1 (en) 2002-10-16 2005-01-06 Amgen, Inc., A Corporation Of The State Of Delaware Human anti-IFN-gamma neutralizing antibodies as selective IFN-gamma pathway inhibitors
US20040157293A1 (en) 2002-11-08 2004-08-12 Evans Glen A. Enhanced variants of erythropoietin and methods of use
US20040091961A1 (en) 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
WO2004043382A2 (fr) 2002-11-08 2004-05-27 Egea Biosciences, Inc. Variants ameliores de l'erythropoietine et methodes d'utilisation
WO2004058988A2 (fr) 2002-12-20 2004-07-15 Amgen, Inc. Agents de liaison inhibant la myostatine
US20040181033A1 (en) 2002-12-20 2004-09-16 Hq Han Binding agents which inhibit myostatin
US20040202655A1 (en) 2003-03-14 2004-10-14 Morton Phillip A. Antibodies to IGF-I receptor for the treatment of cancers
US20040228859A1 (en) 2003-04-02 2004-11-18 Yvo Graus Antibodies against insulin-like growth factor 1 receptor and uses thereof
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
WO2005016970A2 (fr) 2003-05-01 2005-02-24 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
WO2005001025A2 (fr) 2003-05-06 2005-01-06 Syntonix Pharmaceuticals, Inc. Hybrides monomeres/dimeres chimeriques d'immunoglobuline
US20050137329A1 (en) 2003-05-12 2005-06-23 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
WO2004101606A2 (fr) 2003-05-12 2004-11-25 Affymax, Inc. Nouveaux peptides se fixant au recepteur de l'erythropoietine
US20050107297A1 (en) 2003-05-12 2005-05-19 Holmes Christopher P. Novel poly(ethylene glycol) modified compounds and uses thereof
US20060040858A1 (en) 2003-05-12 2006-02-23 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
US7084245B2 (en) 2003-05-12 2006-08-01 Affymax, Inc. Peptides that bind to the erythropoietin receptor
WO2004101600A2 (fr) 2003-05-12 2004-11-25 Affymax, Inc. Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
WO2004101611A2 (fr) 2003-05-12 2004-11-25 Affymax, Inc. Nouveaux peptides se fixant au recepteur de l'erythropoietine
WO2004106373A1 (fr) 2003-05-17 2004-12-09 Centocor, Inc. Composes conjugues d'erythropoietine a demi-vies rallongees
US20040229318A1 (en) 2003-05-17 2004-11-18 George Heavner Erythropoietin conjugate compounds with extended half-lives
US20040266690A1 (en) 2003-05-30 2004-12-30 Chadler Pool Formation of novel erythropoietin conjugates using transglutaminase
WO2005001136A1 (fr) 2003-06-04 2005-01-06 Irm Llc Methodes et compositions pour la modulation de l'expression de l'erythropoietine
US20050008642A1 (en) 2003-07-10 2005-01-13 Yvo Graus Antibodies against insulin-like growth factor 1 receptor and uses thereof
US20050074821A1 (en) 2003-07-15 2005-04-07 Wild Kenneth D. Human anti-NGF neutralizing antibodies as selective NGF pathway inhibitors
WO2005017107A2 (fr) 2003-07-18 2005-02-24 Amgen Inc. Agents de liaison specifiques se liant a un facteur de croissance hepatocyte
US20050118643A1 (en) 2003-07-18 2005-06-02 Burgess Teresa L. Specific binding agents to hepatocyte growth factor
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
US7981669B2 (en) 2003-07-25 2011-07-19 Biovex Limited Viral vectors
WO2005021579A2 (fr) 2003-08-28 2005-03-10 Biorexis Pharmaceutical Corporation Peptides mimetiques epo et proteines de fusion
WO2005025606A1 (fr) 2003-09-09 2005-03-24 Warren Pharmaceuticals, Inc. Erythropoietines a action prolongee pouvant maintenir une activite de protection tissulaire d'une erythropoietine endogene
WO2005081687A2 (fr) 2003-09-30 2005-09-09 Centocor, Inc. Mimeticorps de noyau-charniere humain, compositions, procedes et applications correspondantes
WO2005032460A2 (fr) 2003-09-30 2005-04-14 Centocor, Inc. Mimeticorps de noyau charniere mimetiques de l'epo humaine, compositions, procedes et applications correspondantes
US20050112694A1 (en) 2003-11-07 2005-05-26 Carter Paul J. Antibodies that bind interleukin-4 receptor
WO2005047331A2 (fr) 2003-11-07 2005-05-26 Immunex Corporation Anticorps liant un recepteur de l'interleucine 4
US20050136063A1 (en) 2003-11-21 2005-06-23 Schering Corporation Anti-IGFR antibody therapeutic combinations
US20050143292A1 (en) 2003-11-24 2005-06-30 Defrees Shawn Glycopegylated erythropoietin
US20060111279A1 (en) 2003-11-24 2006-05-25 Neose Technologies, Inc. Glycopegylated erythropoietin
WO2005051327A2 (fr) 2003-11-24 2005-06-09 Neose Technologies, Inc. Erythropoietine glycopegylee
WO2005058967A2 (fr) 2003-12-16 2005-06-30 Pierre Fabre Medicament Nouveau recepteur hybride anti-insuline/igf-i ou recepteur hybride anti-insuline/igf-i et anticorps igf-ir et applications
WO2005063809A1 (fr) 2003-12-22 2005-07-14 Dubai Genetics Fz-Llc Erythopoietine identique a la forme naturelle
US20050192211A1 (en) 2003-12-31 2005-09-01 Emd Lexigen Research Center Corp. Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005063808A1 (fr) 2003-12-31 2005-07-14 Merck Patent Gmbh Proteine hybride fc-erythropoietine a pharmacocinetique amelioree
US20050170457A1 (en) 2003-12-31 2005-08-04 Chadler Pool Novel recombinant proteins with N-terminal free thiol
US20050158822A1 (en) 2004-01-20 2005-07-21 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5'-UTR
WO2005070451A1 (fr) 2004-01-22 2005-08-04 Zafena Aktiebolag Composition pharmaceutique comprenant une erythropoietine non glycosylee
US20050181482A1 (en) 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
WO2005084711A1 (fr) 2004-03-02 2005-09-15 Chengdu Institute Of Biological Products Erythropoietine recombinante pegylee a activite in vivo
WO2005092369A2 (fr) 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugues d'hydroxy-ethyl-amidon et d'erythropoietine
US20060002929A1 (en) 2004-03-23 2006-01-05 Khare Sanjay D Monoclonal antibodies
WO2005100403A2 (fr) 2004-04-09 2005-10-27 Abbott Laboratories Anticorps diriges contre le recepteur de l'erythropoietine et utilisations associees
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
WO2005103076A2 (fr) 2004-04-23 2005-11-03 Cambridge Antibody Technology Limited Variants d'erythropoietine
WO2006002646A2 (fr) 2004-07-07 2006-01-12 H. Lundbeck A/S Nouvelle erythropoietine carbamylee et son procede de production
WO2006013472A2 (fr) 2004-07-29 2006-02-09 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et utilisations
WO2006029094A2 (fr) 2004-09-02 2006-03-16 Xencor, Inc. Derives d'erythropoietine a antigenicite modifiee
WO2006050959A2 (fr) 2004-11-10 2006-05-18 Aplagen Gmbh Molecules favorisant l'hematopoiese
WO2006069202A2 (fr) 2004-12-22 2006-06-29 Amgen Inc. Compositions et procedes impliquant des anticorps diriges contre le recepteur igf-1r
US20150314076A1 (en) * 2005-01-21 2015-11-05 Novo Nordisk A/S Automatic Injection Device with a Top Release Mechanism
WO2006081171A1 (fr) 2005-01-24 2006-08-03 Amgen Inc. Anticorps anti-amyloide humanise
US20070110747A1 (en) 2005-05-03 2007-05-17 Ucb S.A. Binding agents
WO2006138729A2 (fr) 2005-06-17 2006-12-28 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
WO2007000328A1 (fr) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Anticorps se fixant à un épitope sur un récepteur de facteur de croissance insulinomimétique de type 1 et leurs utilisations
US20080166352A1 (en) 2005-07-18 2008-07-10 Amgen Inc. Human anti-B7RP1 Neutralizing Antibodies
WO2007011941A2 (fr) 2005-07-18 2007-01-25 Amgen Inc. Anticorps neutralisants anti-b7rp1 humains
WO2007012614A2 (fr) 2005-07-22 2007-02-01 Pierre Fabre Medicament Nouveaux anticorps anti igf-ir et leur utilisation
US7521048B2 (en) 2005-08-31 2009-04-21 Amgen Inc. TRAIL receptor-2 polypeptides and antibodies
US20090186022A1 (en) 2006-02-23 2009-07-23 Novartis Ag Organic Compounds
US20070253951A1 (en) 2006-04-24 2007-11-01 Gordon Ng Humanized c-Kit antibody
WO2007136752A2 (fr) 2006-05-19 2007-11-29 Glycofi, Inc. Compositions d'érythropoïétine
US20090234106A1 (en) 2006-09-08 2009-09-17 Amgen Inc. Anti-activin a antibodies and uses thereof
WO2008133647A2 (fr) 2006-11-07 2008-11-06 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057458A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057459A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008057457A2 (fr) 2006-11-07 2008-05-15 Merck & Co., Inc. Antagonistes de pcsk9
WO2008063382A2 (fr) 2006-11-07 2008-05-29 Merck & Co., Inc. Antagonistes de pcsk9
US8232372B2 (en) 2006-12-14 2012-07-31 Schering Corp. Engineered anti-TSLP antibody
WO2008125623A2 (fr) 2007-04-13 2008-10-23 Novartis Ag Molécules et procédés de modulation de proprotéine convertase subtilisine/kexine de type 9 (pcsk9)
US8101182B2 (en) 2007-06-20 2012-01-24 Novartis Ag Methods and compositions for treating allergic diseases
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
WO2009055783A2 (fr) 2007-10-26 2009-04-30 Schering Corporation Anti-pcsk9 et méthodes de traitement de troubles du métabolisme lipidique et du cholestérol
WO2009100297A1 (fr) 2008-02-07 2009-08-13 Merck & Co., Inc. Antagonistes de pcsk9 1d05
WO2009100318A1 (fr) 2008-02-07 2009-08-13 Merck & Co., Inc. Antagonistes de 1b20 pcsk9
WO2010029513A2 (fr) 2008-09-12 2010-03-18 Rinat Neuroscience Corporation Antagonistes de pcsk9
WO2010077854A1 (fr) 2008-12-15 2010-07-08 Regeneron Pharamaceuticals, Inc. Anticorps humains à grande affinité contre pcsk9
WO2010075238A1 (fr) 2008-12-23 2010-07-01 Amgen Inc. Protéines de liaison au récepteur cgrp humain
WO2011037791A1 (fr) 2009-09-25 2011-03-31 Merck Sharp & Dohme Corp. Antagonistes de pcsk9
WO2011053759A1 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes de la pcsk9 avec anticorps fab ax189 et ax1, et variantes afférentes
WO2011053783A2 (fr) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Antagonistes et variants ax213 et ax132 pcsk9
WO2011072263A1 (fr) 2009-12-11 2011-06-16 Irm Llc Antagonistes de pcsk9
WO2011111007A2 (fr) 2010-03-11 2011-09-15 Rinat Neuroscience Corporation Anticorps présentant une liaison à l'antigène dépendante du ph
WO2012054438A1 (fr) 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (fr) 2010-12-22 2012-06-28 Genentech, Inc. Anticorps anti-pcsk9 et procédés d'utilisation
WO2012101251A1 (fr) 2011-01-28 2012-08-02 Sanofi Anticorps humains dirigés contre la pcsk9 destinés à être utilisés dans des procédés de traitement basés sur des schémas posologiques particuliers
WO2012101253A1 (fr) 2011-01-28 2012-08-02 Sanofi Compositions pharmaceutiques comprenant des anticorps humains contre pcsk9
WO2012101252A2 (fr) 2011-01-28 2012-08-02 Sanofi Anticorps humains contre pcsk9 pour utilisation dans des procédés de traitement de groupes particuliers de sujets
WO2012109530A1 (fr) 2011-02-11 2012-08-16 Irm Llc Antagonistes de pcsk9
US20130064825A1 (en) 2011-05-10 2013-03-14 Amgen Inc. Methods of treating or preventing cholesterol related disorders
US20130072880A1 (en) * 2011-09-16 2013-03-21 Tyco Healthcare Group Lp Fluid Delivery Device with Filtration
WO2014099984A1 (fr) 2012-12-20 2014-06-26 Amgen Inc. Agonistes du récepteur apj et leurs utilisations
US20140274874A1 (en) 2013-03-14 2014-09-18 Amgen Inc. Variants of tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
WO2014152012A2 (fr) 2013-03-14 2014-09-25 Amgen Inc. Variants d'inhibiteur tissulaire de la métalloprotéinase type iii (timp-3), compositions et procédés
US20150320938A1 (en) * 2014-05-06 2015-11-12 Biomet Biologics, Llc Single Step Desiccating Bead-in-Syringe Concentrating Device

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COHEN ET AL., CLINICAL CANCER RES., vol. 11, 2005, pages 2063 - 2073
LEI ET AL., WORLD J. GASTROENTEROL., vol. 19, 2013, pages 5138 - 5143
LU ET AL., J. BIOL. CHEM., vol. 279, 2004, pages 2856 - 2865
MALONEY ET AL., CANCER RES., vol. 63, 2003, pages 5073 - 5083
THAKUR ET AL., MOL. IMMUNOL., vol. 36, 1999, pages 1107 - 1115
VARGEHES ET AL., CANCER GENE THER., vol. 9, no. 12, 2002, pages 967 - 978

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020081479A1 (fr) * 2018-10-15 2020-04-23 Amgen Inc. Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
WO2021163504A1 (fr) 2020-02-13 2021-08-19 Amgen Inc. Formulations d'anticorps anti-tslp humains, et méthodes de traitement de maladie inflammatoire
WO2021168100A1 (fr) 2020-02-18 2021-08-26 Amgen Inc. Formulations d'anticorps anti-tslp humains et leurs procédés d'utilisation
WO2022146931A1 (fr) * 2021-01-03 2022-07-07 Fpin Llc Auto-injecteurs amortis
US11464902B1 (en) 2021-02-18 2022-10-11 Fresenius Kabi Deutschland Gmbh Wearable medicament delivery device with compressible reservoir and method of use thereof
US11311666B1 (en) 2021-02-18 2022-04-26 Fresenius Kabi Deutschland Gmbh Modular wearable medicament delivery device and method of use thereof
US11872369B1 (en) 2021-02-18 2024-01-16 Fresenius Kabi Deutschland Gmbh Wearable medicament delivery device with leakage and skin contact sensing and method of use thereof
US11497847B1 (en) 2021-02-19 2022-11-15 Fresenius Kabi Deutschland Gmbh Wearable injector with adhesive substrate
US11413394B1 (en) 2021-02-19 2022-08-16 Fresenius Kabi Deutschland Gmbh Display for wearable drug delivery device
US11344682B1 (en) 2021-02-19 2022-05-31 Fresenius Kabi Deutschland Gmbh Drug supply cartridge with visual use indicator and delivery devices that use the same
US11426523B1 (en) 2021-02-19 2022-08-30 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including a removable cartridge
US11406755B1 (en) 2021-02-19 2022-08-09 Fresenius Kabi Deutschland Gmbh Sensing fluid flow irregularities in an on-body injector
US11633537B1 (en) 2021-02-19 2023-04-25 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including a pre-filled cartridge
US11607505B1 (en) 2021-02-19 2023-03-21 Fresenius Kabi Deutschland Gmbh Wearable injector with sterility sensors
WO2022226342A2 (fr) 2021-04-23 2022-10-27 Amgen Inc. Anticorps anti-tslp modifiés
WO2022226339A1 (fr) 2021-04-23 2022-10-27 Amgen Inc. Compositions d'anticorps anti-tslp et leurs utilisations
US11529459B1 (en) 2021-04-30 2022-12-20 Fresenius Kabi Deutschland Gmbh Wearable injector with adhesive module
US11504470B1 (en) 2021-04-30 2022-11-22 Fresenius Kabi Deutschland Gmbh Deformable drug reservoir for wearable drug delivery device
US11351300B1 (en) 2021-04-30 2022-06-07 Fresenius Kabl Deutschland GmbH Drug dispensing system with replaceable drug supply cartridges
US11419976B1 (en) 2021-04-30 2022-08-23 Fresenius Kabi Deutschland Gmbh Wearable drug delivery device with pressurized fluid dispensing
US11717608B1 (en) 2021-05-03 2023-08-08 Fresenius Kabi Deutschland Gmbh Drug delivery assembly including an adhesive pad
US11484646B1 (en) 2021-05-04 2022-11-01 Fresenius Kabi Deutschland Gmbh Sealing systems for a reservoir of an on-body injector

Also Published As

Publication number Publication date
CN110709121B (zh) 2022-06-24
MX2019014615A (es) 2020-02-07
EP3634546A1 (fr) 2020-04-15
CA3066399A1 (fr) 2018-12-13
JP2020523050A (ja) 2020-08-06
AU2024201097A1 (en) 2024-03-14
JP7200134B2 (ja) 2023-01-06
AU2018282077B2 (en) 2023-11-23
US20230138654A1 (en) 2023-05-04
CN110709121A (zh) 2020-01-17
AU2018282077A1 (en) 2019-11-28
JP2023030073A (ja) 2023-03-07
US11904143B2 (en) 2024-02-20

Similar Documents

Publication Publication Date Title
AU2018282077B2 (en) Torque driven drug delivery device
US20200316303A1 (en) Autoinjector with shock reducing elements
US20200390977A1 (en) Drug delivery device with a rotatable drive mechanism
EP3478342A1 (fr) Dispositif d'administration de médicament présentant un risque réduit au minimum de fracture de composant lors d'événements d'impact
US20200114082A1 (en) Drug delivery device having damping mechanism
WO2016138434A1 (fr) Dispositif d'administration de médicament ayant un mécanisme de protection d'aiguille présentant un seuil réglable de résistance au mouvement de l'élément de protection d'aiguille
US20210338936A1 (en) Drug delivery device having dose indicator
EA041074B1 (ru) Устройство доставки лекарственного средства, имеющее демпферный механизм
WO2022146931A1 (fr) Auto-injecteurs amortis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18733474

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019561838

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018282077

Country of ref document: AU

Date of ref document: 20180604

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3066399

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018733474

Country of ref document: EP

Effective date: 20200108